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ABSTRACT
Bioconjugation is an important tool for studying complex biological systems, with site-specificity
being the major challenge. Reactions based on amino acid derived organocatalysts have been
widely used in organic synthesis, particularly for the asymmetric synthesis of small molecules but
this concept has not been vastly explored on biomolecules. To combat these limitations, two
chemical strategies are developed to effectively attach synthetic molecules site specifically to
proteins. First, a protein modification technique based on conjugation at a non-native functional
handle, an aldehyde or ketone, is developed. This functional handle is chemically introduced onto
the biomolecules before undergoing the organocatalyzed aldol reaction, resulting in a stable
bioconjugate. Next, the focus is on the development of a bioconjugation technique based on a
native functionality found on proteins. The site of interest for this technique is the a-amine of the
N-terminus, which stands out as a unique reactive site for site-specific modification strategies. This
involves a reaction between an aldehyde containing molecule and one with either asparagine or
glutamine at the N-terminal, resulting in formation of a bioconjugate product. Both methods
demonstrate similar advantages, such as selectivity, specificity, and broad applicability, including
their potential use for the synthesis of homogeneous antibody-drug-conjugates.
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Chapter 1: General Overview of Peptide Chemistry and Methods and
Applications of Bioconjugation

1.1 General Introduction to Amino Acids and Peptide Structure

Amino acids serve as the building blocks of peptides and proteins and also participate as
intermediates in metabolic processes. There are 20 naturally occurring amino acids, 9 of which
cannot be synthesized in the body and must be attained through diet. The importance of supplying
the body with essential amino acids was demonstrated by Willcock and Hopkins in 1906. A study
was conducted where mice were starved of a protein that provided essential amino acids and the
addition of tryptophan allowed the mice to survive for a longer period of time. The further addition
of lysine restored normal growth. This study showed that the biological importance of the protein
being fed to the growing mice to aid in their growth was dependent on the protein’s ability to
supply the amino acids the mice cannot produce on their own as well as the importance in amino
acids in keeping the mice alive. Amino acids make up the structure of tissue and cells, aid in
cardiovascular health by producing nitric oxide that lowers blood pressure, are metabolized for
energy, and perform various other functions in the body.
Amino acids, having an amino group on the N-terminus and a carboxylic acid group on the Cterminus, differ only by their side chains. The amino group, carboxyl group, and side chain are all
bound by the central α-carbon. Amino acids are chiral in nature, having a non-superimposable
mirror image and possessing 4 different substituents attached to the α-carbon. This allows them to
exist as two enantiomers, D(R) and L(S), with the L-form being predominant in nature, while the
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D-form can arise due to mutations, with the exception of achiral glycine. The side chains give the
amino acids their properties, making them polar, non-polar, acidic, basic, aromatic, aliphatic,
sulfur contains, ect. The properties of the side chains dictate the amino acids’ behavior, for
example, the acid and base properties of amino acids containing ionizable groups is influenced by
changes in environmental pH. These factors further influence biomolecules that are made up of
amino acids, such as proteins, and their intermolecular and intramolecular interactions.

Peptides are chains of 2 to 50 amino acids joined together through amide bonds. Amide bond
formation is a condensation reaction between the carboxyl group of one amino acid and the amino
group of another amino acid. Peptides play a role in gene regulation, protein targeting, cell
singling, and metabolism. There are over 7000 naturally occurring peptides and just like amino
acids, they have important biological activities that are essential to maintaining good health.
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1.2 Peptide Chemistry

Peptides play a critical role in necessary physiological and biochemical processes. Peptides are
essential to many aspects of biomedical research, contributing to the industry shift toward
developing biologics as drug candidates and expanding the peptide-therapeutics toolbox. As stated
before, peptides play a role in singling pathways. For example, Insulin is a peptide-hormone used
in the treatment of diabetes, which is a group of diseases characterized by high blood glucose
levels.1 Insulin is given as a treatment for diabetes and binding of the insulin molecule to the insulin
receptor causes a cascade of signaling events that allows for the cellular uptake of glucose. This
51-amino-acid peptide is essential for the prevention of complications associated with diabetes,
such as a heart attack, nerve and kidney damage, hearing impairment, and skin conditions. Besides
signal transduction, other important applications of peptides include inhibitors of protein-protein
interactions and regulators of ion channels.2,3
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1.3 Solid Phase Peptide Synthesis

In order to expand that peptide-therapeutics toolbox, methods of chemical synthesis are required
to mimic naturally occurring peptides and develop new peptide drug candidates. Solid phase
peptide synthesis (SPPS) is the step-wise assembly of amino acid monomers through a continuous,
repetitive cycle of activation, attachment of adjacent amino acids, and deprotection until the
desired peptide is achieved.4 Peptides can be synthesized in solution or on solid support, with the
latter being the preferred synthesis method based on its ease of purification. Chemical peptide
synthesis produces various side products and uses excess reagents that can interfere with
subsequent steps in the synthesis process. Using beads and growing the peptide on solid support
allows for easier purification, isolation, and characterization after each step in the synthesis cycle.
Peptides are read from N-terminus to C-terminus, however, they are attached to the solid support
at the C-terminus and are synthesized from the C-terminus to N-terminus. The first step in SPPS
is swelling of the sponge-like resin; this is done to maximize the exposure of functional groups to
incoming reactants. The resin has a reactive functional group, in this case an amine, that is first
deprotected then reacts with the activated carboxylic acid of the fluorenylmethyloxycarbonyl
(Fmoc)-protected amino group of the amino acid.5 Protecting groups (PG) are used to prevent
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unwanted side-reactions of reactive functional groups. If the amine was not protected, the amino
acid, which is used in excess to enhance conversion rates, could join to the resin indefinitely by
linking to one another to form a chain. Coupling reagents make the carboxylic acid more reactive
and are used to increase the speed and efficiency of the reaction, as well as to control racemization.
The time of attachment of the amino acid to the resin and to the growing peptide chain ranges from
5 minutes to 4 hours depending on the coupling reagents used. After the first amino acid is loaded
onto the resin, excess reagents are washed away and the Fmoc protecting group is removed in a
deprotection step by a 20-minute treatment with base, typically 20% piperdine in DMF. Following
washing, another amino acid is activated, added to the growing peptide on solid support, and the
cycle is repeated until the desired peptide is made. Washing is essential between coupling and
deprotection to prevent residual piperdine from removing the Fmoc protecting group from the
newly introduced amino acid. This washing or purification step is one of the benefits of
synthesizing peptides on solid support since the peptide remains on the bead and all unwanted
reagents and byproducts are easily washed away. Once the desired peptide is synthesized, the final
Fmoc protecting group is removed. Side chains of reactive amino acids are also protected during
the synthesis process. Those protecting groups are removed and the peptide is cleaved from the
resin simultaneously using TFA. Scavengers, such as water and TES, are used to react with and
prevent those side chain protecting groups from reattaching to the peptide. The peptide is further
analyzed by HPLC to determine its purity and mass spectrometry to verify its molecular weight.

5

1.3.1

Solid Support Resins

The solid support upon which the growing polypeptide chain is built upon is chosen based on its
physical stability. The bead itself can be made from different polymers, such as polystyrene (PS)
and polyethylene glycol (PEG). PS is an aromatic hydrocarbon polymer prepared as a small
spherical bead containing 1%-2% divinylbenzene (DVB) as a crosslinking agent, making it
insoluble in all common solvents.6 This insoluble bead is a benefit of SPPS since the peptide
remains on the solid support and all unwanted reagents and byproducts are washed away during
repeated washing steps. The cross-linked resin swells in aprotic solvents, such as DMF, DCM, and
toluene. Depending on the DVB percentage, the resin can swell from 2 to 6 times its original
volume in DCM to allow more reagents into the core of the matrix for reaction. Swelling the resin
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increases the reaction conversion and shortens the reaction time by making more active sites
accessible for reaction. Bead size is also critical because if they are too small, filtration time will
be extended. During the peptide synthesis process, there are multiple deprotection steps as well as
various synthetic conditions and the resin chosen will withstand repeated exposure to those
conditions, allowing for rapid filtration and only being removed selectively at the end of synthesis.

Another important factor to consider when choosing a solid support resin is its functionality. There
are many resin and linker combinations available that allows for synthetic flexibility. For example,
one of the most popular resins used in SPPS is Fmoc-NH Rink Amide resin. This resin contains a
protected amine group that reacts with the first incoming amino acid to form an amide bond. When
cleaved from the polystyrene bead, the C-terminus of the peptide contains an amide functional
group. Wang resin is another common polystyrene resin used but it has a hydroxyl functional group
and produces a carboxylic acid at the C-terminus of the peptide after cleavage from the resin.
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1.3.2

Activating and Coupling Reagents

As stated before, the formation of an amide bond requires a coupling reaction consisting of two
steps. In the first step, the carboxy moiety is activated and in the second, the amino group is
acylated. Carbodiimides, such as DCC and DIC, are used as activators in both solution and solidphase peptide synthesis for the activation of carboxylic acids. For solid-phase synthesis, DIC is
the preferred carbodiimide because the corresponding urea by-product is soluble in standard
solvents and can be readily removed during the washing steps in SPPS. DCC is preferred for
solution synthesis because the urea byproduct, Dicyclohexylurea, is insoluble and the precipitate
can be removed by filtration. Following activation of the carboxy moiety to form O-acylisourea,
HOAt or HOBt can be used to minimize racemization of the amino acid.7 The primary amine reacts
with the activated OAt or OBt ester intermediates, resulting in amide bond formation. Coupling
an amino acid to resin requires DMAP as an additive in catalytic amounts in order to prevent
unwanted racemization.8
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Aminium-based reagents, such as HBTU and TBTU, are also used as coupling reagents, both
demonstrating resistance to racemization and only differ by their counterions. First, DIPEA reacts
with the carboxylic acid of the incoming amino acid followed by formation of a benzotriazole
active ester intermediate and lastly, nucleophilic attack of the intermediate by the unprotected Nterminal amine of the peptide. These reagents are used in SPPS because the by-products are soluble
in water and in standard organic solvents, making purification on solid support easy. Excess HBTU
and TBTU can block elongation of the peptide by reacting with the unprotected N-terminal of the
growing peptide, which results in the formation of a guanylidine moiety. Due to this limitation,
these reagents should be used in equal molar amounts to the carboxy moiety.
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1.3.3

N-Terminal Modifications

Following biosynthesis, proteins undergo enzymatic modifications referred to as post-translational
modifications (PTM), which consists of introducing a new functional group, modifying an existing
functional group, cleaving a peptide bond, or forming covalent bonds. These modifications include
acetylation, phosphorylation, cyclization via disulfide bridges, and fluorescent label incorporation.
Modifications can occur anywhere in the protein including the side chains of amino acids, the Ctermini, and the N-termini for example, nucleophilic functional groups of amino acids often
undergo PTMs, such as the hydroxyl group of serine or the amine group of lysine. These additional
10

changes are done after synthesis in order to get mature proteins that interact with other cellular
molecules, regulate activity and localization, or perform other various functions.

Similarly, following chemical synthesis, peptides can undergo modifications. For example,
peptides can be labeled via acetylation at their free N-terminal amine. N-acetylation is used to
increase peptide stability by preventing N-terminal degradation. This modification also removes
the positive charge on the N-terminal of peptides, which helps the peptide to further mimic
naturally acetylated proteins.9 Adding fluorescein, which is a fluorophore used as a fluorescent
tracker, to study peptide interactions and conduct localization studies at a cellular level is another
example.10 The N-termini of peptides and proteins can also be modified to incorporate a new
functional group such as aldehydes and ketones. There are numerous methods to enzymatically
and chemically incorporate an aldehyde onto the peptide or protein. For example, N-terminal serine
or threonine residues can be converted to aldehydes chemically via oxidative cleavage using
periodate.11 Modified proteins have multiple uses, including bioconjugation.
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1.4 General Overview of Bioconjugation

Bioconjugation is a chemical strategy which involves the coupling of a biomolecule, such as a
protein or polypeptide, with any organic, inorganic, or another biomolecule. This attachment of
synthetic molecules to proteins with desired structure and function allows for the formation of
hybrid materials that can capitalize on the properties of both components. The modification of
proteins to install new functions and to diversify the protein structure is widely known in nature.
However, the chemical methods available limits our ability to achieve such selective modifications
of proteins. The chemical reaction at a single site on a biomolecule to generate homogenous
12

constructs in the presence of various reactive functional groups in both chemo- and regioselective
manner is highly challenging. This challenge is further augmented by the requirement for
biologically relevant conditions (for example, aqueous media, 37oC temperature, and mild pH (6–
8) to maintain the protein structure and/or function. Nevertheless, chemical methods have emerged
for the modification of proteins with natural and unnatural amino acids in protein molecules.

An ideal bioconjugation reaction must fulfill specific requirements, such as the presence of
orthogonal functional groups which can be installed easily on proteins or biomolecules via
chemical or protein engineering and should have high flexibility for modification. The reaction
also should be highly specific between endogenous functional groups to avoid side reactions with
biological molecules. The reaction should be non-toxic and does not require the use of metal
catalyst and should be compatible in aqueous environment or biological medium. Lastly, the
reaction should be irreversible, and the strong covalent link should be inert to biological reactions.

1.5 Native Methods of Bioconjugation

Many methods have been developed to conjugate a molecule to native functionalities present in
proteins via amino acid side-chains, such as lysine, cysteine, tyrosine, and tryptophan. These
techniques include disulfide bond formation between two cysteines, alkylation and acylation of
primary amines such as lysine, thiazolidine ring formation between cysteine and an aldehyde,
Pictet-Spengler Cyclization of tryptophan and an aldehyde, and Native Chemical Ligation between
cysteine and a thioester that results in amide bond formation.12,13,14,15,16 When applied to protein
labeling, these reactions tend to be non-selective since proteins contain multiple copies of targeted
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residues on their surface that are usually present in large quantities and hinder selectivity.
Bioconjugation methods dependent on the presence of native amino acid residues often lack
chemoselectivity and efficiency.

1.5.1

Thiol-Maleimide Chemistry

Cysteine residues are abundant in peptides and proteins therefore, they are also commonly used as
a source for bioconjugation. Cysteine’s side chain contains a thiol group that is used to
synthetically modify proteins and peptides.12 Two cysteines can form a disulfide bridge by the
oxidation of the sulfhydryl groups. This can be done intramolecularly to stabilize a protein or
intermolecularly to create protein dimers or for bioconjugation. The interconversion between the
thiol and disulfide is a redox reaction, which can result in disulfide shuffling or thiol exchange
with the other abundant thiol containing molecules in the body. For example, thiol-maleimide
chemistry involves a Michael Reaction between a biomolecule containing a thiol group with a
maleimide containing label.17 Maleimides are electrophilic with high selectivity toward thiols
therefore this reaction is also used for bioconjugation. However, the maleimide-thiol adduct is
exchangeable in physiologically relevant conditions with free cysteine containing biomolecules in
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the body, for example, serum albumin, the most abundant blood plasma protein. In humans, human
serum albumin normally constitutes 50% of human plasma protein. Another free cysteine
containing biomolecule is glutathione, which is a Glutamate-cysteine, glycine tripeptide that plays
a vital role in detoxification and serves as a neuromodulator for NMDA and AMPA receptors.18
Maleimide’s selectivity for free thiols makes this conjugation method unreliable since there are a
plethora of essential biomolecules containing free cysteines in the human body.

1.5.2

Alkylation of primary amines

Like thiols, primary amines are also naturally occurring functionalities found on peptides and
proteins, such as the side chain of lysine and the N-termini. Primary amines can readily undergo
reactions with a range of alkylating and acylating agents including activated esters and anhydrides.
For example, the condensation reaction of primary amines with an aldehyde to form an imine can
be used for bioconjugation and the reversible imine can be further stabilized by reductive
amination. This is typically done using NaBH3CN as a reducing agent under acidic conditions to
preserve the cyanoborohydride reductant, however this environment can disrupt the tertiary
structure of the biological molecule. Reduction of the iminium intermediates been achieved at
room temperature and neutral pH using [Cp*Ir-(bipy)(H2O)]SO4 through iridium-catalyzed
transfer hydrogenation.13 Although the iridium catalyst allows for reductive amination in a
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biological environment, the problem with using Lysine, as well as other amino acids, is that the
targeting of side-chains results in uncontrollable labeling of biomolecules.

1.6 Bioorthogonal Methods of Bioconjugation

There is an increasing need for chemical strategies that can effectively attach synthetic molecules
site specifically to proteins. As a result, many newer bioorthogonal techniques for protein
modification involves the introduction of unnatural amino acids, or exogenous functionality onto
a protein, which is then utilized for site-selective conjugation.19 Some of the most used reactions
include Cu1-Catalyzed Azide-Alkyne, the improved catalyst-free Strain-Promoted Azide-Alkyne
reaction, and Hydrazone/Oxime ligation, which takes advantage of the various methods to
genetically or chemically incorporate an aldehyde onto a biomolecule. Bioconjugation methods
for incorporated functionalities will be further discussed as well as the limitations of these
methods.
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1.6.1

CuI-Catalyzed Azide-Alkyne Cycloaddition (CuAAC)

There are multiple protein modifications that incorporate an exogenous functionality onto a protein
for site-selective conjugation. For example, the copper-catalyzed click reaction takes place
between an azide and an alkyne, with either of those functionalities being chemically or genetically
incorporated onto a biological molecule. This popular bioorthogonal method, as well as many
others, is limited in its applicability to a biological environment. Although this reaction is highly
specific and proceeds rapidly, the large amount of Cu(I) used for this type of bioconjugation can
cause toxicity to living cells and tissue. The biological damage is attributed to the generation of
reactive oxygen species (ROS) from O2; the structure and function of biomolecules is
compromised in the presence of ROS, leading to the digestion of amino acids and breakdown of
peptide chains and protein backbones.20
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Strain-promoted azide-alkyne cycloaddition (SPAAC), which is activated by ring strain, has been
developed to improve the CuAAC reaction’s compatibility in a biological environment. The
alkynes used in this reaction have high energy ring strain, which eliminates the need for potentially
cytotoxic copper. However, the major setback with using SPAAC is that the cyclooctyne
component that drives the reaction is hydrophobic and relatively large in size. When used for
bioconjugation, these cyclooctynes can change the properties of the biological molecule.21 Also,
cyclooctynes can undergo nucleophilic addition with other naturally occurring, ubiquitous cellular
components, such as glutathione.22 When used for bioconjugation, this method is limited by its
specificity, lack of freedom for placement of functional groups within the target protein, and the
potential for structural change of the protein.
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1.6.2

Hydrazone/Oxime ligation

Hydrazone and oxime ligations are often used for bioconjugation and involves the incorporation
of the non-native aldehyde or ketone functional group onto a protein; this bioorthogonal reaction
is then utilized for site-selective conjugation. This transamination reaction takes place by reacting
a ketone or aldehyde with hydrazides and hydroxylamine to produce hydrazone and oxime
linkages, respectively. Ketones and aldehydes can be incorporated into biomolecule via multiple
methods, including but not limited to PLP-mediated transamination of multiple N-terminal
residues as well as periodate oxidation of serine and threonine residues.23,11

However, this approach is limited by slow reaction kinetics, requirement of acidic (pH 5–6)
reaction conditions, high concentrations of harmful catalysts, cross-reactivity with metabolites and
the reversibility of the reaction in the presence of water. The requirement of acidic conditions can
disrupt the intramolecular forces within the protein, which is important for maintaining its structure
and function. The susceptibility of the hydrazone/oxime linkage to reversibility is especially
dangerous when used in drug delivery, for example, which can cause the drug to dissociate from
a delivery vehicle before reaching its target, resulting in side-effects or inefficient medical
treatments. As stated before, an irreversible, stable covalent linkage is one of the requirements for
an ideal bioconjugation technique but is not accomplished using this method.
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1.7 Applications of Bioconjugation

The utility of bioconjugates has been explored in a variety of contexts including determining
protein biodistribution and purification, revealing enzyme function, imaging specific biomarkers,
light harvesting, drug delivery, water remediation, and tissue engineering (Figure 1.6). For
example, PEGylation is a chemical strategy that can be used to improve pharmacological
properties of peptide and proteins used for therapeutics. This technique involves linking one or
more PEG (polyethylene glycol) molecules to peptides and proteins and this strategy has been
proven to be a solution to protein instability and their short circulation time in the blood while
resulting in minimal loss of biological activity. For example, insulin is a peptide hormone involved
in metabolism by assisting in the absorption of glucose into the tissues from your blood.
PEGylation enhances the stability and potency of insulin by increasing its solubility due to the
PEG groups’ hydrophilicity, decreasing accessibility for proteolytic enzymes, and increasing its
size to reduce kidney filtration. Bioconjugation is also used in the synthesis of antibody-drug
conjugates (ADC), which is the application most relevant to this project and will be discussed in
further detail.
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1.7.1

Antibody-Drug-Conjugates (ADC)

An ADC is an antibody connected via a linker to a small-molecule drug, through a method of
bioconjugation. The antibody selectively recognizes and binds an antigen that is overexpressed on
a tumor cell’s surface. Ideally, the ADC binds to the antigen of the cancer cell, and in certain cases
resulting in internalization of the ADC-antigen complex through the process of receptor-mediated
endocytosis. Once inside of the cell, the ADC-antigen complex it is degraded by lysosomes,
releasing the active cytotoxic drug inside of the cancer cell. Free drug causes cell death through
either tubulin polymerization inhibition or DNA binding and damage depending on the drug’s
mechanism of action. The desired effect of ADCs is the target-dependent killing of tumor cells
expressing high levels of the target antigen and cell. However, side effects can be caused by targetdependent toxicity and the killing of normal cells that express low levels of target antigen, or by
target-independent toxicity caused by free drug entering into normal cells. Free drug can be
released by ADC catabolism or by unstable labile linkers between the antibody and the drug,
releasing free drug into the plasma before the ADC reaches its intended target cell.
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Mylotarg (Gentuzumab) (Figure 1.8, A) is an ADC that demonstrated promising activity in
clinical trials and was granted accelerated approval by the FDA in 2000. The drug, Calicheamicin,
works by causing DNA cleavage, resulting in cell death. It targets the protein CD33, which is
overexpressed in Acute Myeloid Leukemia, a cancer that affects the blood and bone marrow and
usually affects adults above age 40. The attachment site between the drug and the antibody contains
a hydrazone linkage as well as a disulfide bond. This ADC was withdrawn from the market in
2010 after subsequent clinical data raised safety concerns. The linker was unstable and released
50 % of bound drug in 48 hours.24 This could be attributed to the reversible hydrazone linkage or
reduction to free thiols or exchange of the disulfide bond with other thiol containing biomolecules
in the body.

Adcetris (Brentuximab Vedotin) (Figure 1.8, B) is an ADC currently available on the market that
targets the protein CD30, which is expressed in Hodgkin’s Lymphoma.25 Hodgkin's lymphoma is
a cancer of the lymphatic system, which is part of your immune system that may affect people of
any age but is most common in those 20-40 years old and those over 55 years old. The drug,
Monomethyl Auristatine E (MMAE), is an antimitotic drug that kills cell by inhibition of mitosis
and cell division. The protein targeting antibody and the cytotoxic drug are joined through a
Valine-Citrulline dipeptide that is cleavable by intracellular proteases, such as Cathepsin B,
resulting in drug release. The attachment site also contains a succinimide ring made through a
thiol-maleimide linkage, which is essential for keeping the ADC together until it reaches its target.

Lastly, Kadcyla (Trastuzumab) (Figure 1.8, C) is also a currently available ADC and it targets the
HER2 receptor, which is overexpressed in breast cancer.26 Breast cancer is the second most
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common cancer-causing death for women in the US, after lung cancer. However, since 1989, the
number of women who have died from breast cancer has steadily decreased thanks to early
detection and treatment improvements. The drug, Mertansine, works by disrupting microtubule
function, resulting in compromised structure and shape of cells and eventually cell death.
Mertansine is connected to the HER2 receptor targeting antibody by a thiol-maleimide linkage as
well.

Studies were conducted to assess the in vivo stability of the succinimide ring in antibody drug
conjugated.27 The study demonstrated that partially buried environment allowed for succinimide
ring hydrolysis, preventing maleimide exchange and improved conjugate stability. However, if the
linkage exists in a highly solvent-accessible site, maleimide exchange of the linker-drug will occur
with albumin, cysteine, or reduced glutathione in the plasma. The instability of the ADC linker
can lead to unintended drug release before the ADC reached that intended cancer cells. Based on
the limitations highlighted here, there is clearly a need to expand the bioconjugation toolbox and
develop other methodologies that would result in a more stable linkage between the antibody and
the drug (Scheme 1.5).
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Besides the linkage site, another important issue to consider with designing ADCs is the Drug-toAntibody Ratio (DAR). The Drug-to-Antibody ratio refers to the number of drugs loaded to a
single antibody. The use of amino acid side chains where the drug can attach to multiple functional
groups in an uncontrollable manner can result to a heterogeneous DAR distribution. There is no
batch-to-batch consistency, meaning some ADCs will have 2 drugs attached while another may
have 7 drugs attached. There are limitations associated with high drug loading, such as fast
clearance or removal of the ADC from the body so the drug does not have enough time to perform
its intended function.28 High drug loading is also associated with high toxicity and disruption of
structure, the latter can result in the antibody losing its binding properties.28
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1.8 Thesis Objectives

Post-translational modification of proteins to install new functionality is widely known in nature,
yet similar selectivity and efficiency is currently unattainable from the available chemical methods.
Single-site biomolecule functionalization to generate homogeneous constructs in the presence of
amino acids with diverse reactivity in both a chemo- and regioselective manner is an exceptional
challenge, which is further exacerbated by the requirement for non-denaturing conditions. I
hypothesized that by using the aldehyde handle we could make a stable irreversible carbon-carbon
bond, which could be formed by reaction with a ketone in the aldol reaction. Organocatalyst, in
the form of amino acids and peptides, will be used for carrying out the aldol reaction, which will
increase the rate of this bioconjugation reaction under physiologically relevant conditions. The
goal is to demonstrate an N-terminal modification reaction that is applicable to a wide range of
peptides and proteins. The organocatalyzed aldol reaction is expected to be site-specific, rapid,
and occur under mild reaction conditions. I will illustrate the diversity of this reaction for
chemoselective, site-specific bioconjugation on a series of peptides and protein substrates while
showing this method can be used to synthesize ADCs with a 1:1 DAR.

Following the development of the site-selective protein modification technique based on
conjugation at a non-native functional handle, an aldehyde or ketone, the focus shifts to the
development of a bioconjugation technique based on a native functionality found on proteins. The
a-amine of the N-terminus stands out as a unique reactive site for site-specific modification
strategies because it can react with the side chain of the amino acid present on the N-terminus and
an aldehyde to form a biconjugate project. In addition to known methods developed for cysteine,
serine, threonine, and tryptophan, I hypothesize asparagine (Asn, N) and glutamine (Gln, Q) are
25

capable of reacting with an external aldehyde and forming a bioconjugate product as well. This
method will demonstrate similar advantages as the first method, such as selectivity, specificity,
and its broad applicability, including its use in protein purification and in the synthesis of
homogeneous antibody-drug-conjugates.
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Chapter 2: Organocatalytic Aldol Reaction for Bioconjugation

2.1 Chapter Objectives

Amino acids and/or peptides could be used for the conjugation of proteins by catalyzing the aldol
reaction, which would lead to carbon−carbon bond formation at the site of conjugation. While the
efficiency and selectivity of the proposed amino-acid-catalyzed reaction may be impeded by the
presence of a variety of functional groups within complex biomolecules, I envisioned that careful
use of particular amino acids or peptides would serve as highly reactive catalysts for the desired
transformations under physiologically relevant conditions. The interaction between the amino
group of the catalyst and the ketone guide its selectivity by formation of an iminium ion-enamine
complex. The ability to achieve high levels of chemo- and regioselectivity and fast reaction
kinetics with aldehydes and ketones under aqueous conditions by using well-designed amino-acidderived organocatalysts suggests that they could be very attractive for the development of a new
site-selective bioconjugation method leading to the modification at the N-terminus of proteins. In
addition, this method has the potential to generate a chiral center at the site of bioconjugation with
high stereoselectivity through judicious organocatalyst selection, which may be of therapeutic
significance.
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The goal of this chapter is to demonstrate the applicability of the aldol reaction using amino acids
as organocatalysts on biomolecules, specifically peptides. The biomolecule substrates start small,
a simple amino acid, and increase in size and complexity. Amino acid catalyzed aldol reaction has
never been applied to biomolecules, so the first step was incorporating either of the functionalities
required for the aldol reaction, an aldehyde or ketone, onto the amino acid. After this methodology
was demonstrated on an amino acid, the next step was to synthesize and apply this reaction to
peptides. The peptides are of varying lengths and contain different reactive functional groups on
the side chains of the amino acids. From these studies, I was able to optimize the reaction
conditions and illustrate that organocatalysts promoted the reaction rapidly in an aqueous
environment at neutral pH. This is essential in fulfilling the goal of the overall project, which is to
apply this chemistry on complex proteins without interrupting their native structure and function.
Lastly, the substrate scope will be broad, including both aromatic and aliphatic aldehydes and
ketones, as well as conjugation demonstrated between (1) small molecule ketones and biomolecule
aldehydes, (2) small molecule aldehydes and biomolecule ketones, and (3) biomolecule aldehydes
and biomolecule ketones.
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2.2 Introduction
2.21 Aldol Reaction
An aldol reaction occurs between an aldehyde or ketone and another carbonyl containing molecule.
The enolate of the aldehyde or ketone undergoes nucleophilic attack on an electron deficient
carbonyl of another molecule, forming a β-hydroxy carbonyl that links the two starting molecules
via a carbon-carbon bond. Furthermore, the aldol product formed can undergo condensation and
be dehydrated if heat is applied. This yields an irreversible αβ-unsaturated aldehyde or ketone.
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Scheme 2.1 | Aldol Reaction.

The first step of the reaction, which is formation of the enolate, can be catalyzed under basic or
acidic conditions. Base catalysis results in abstraction of a hydrogen from an alpha carbon adjacent
to the carbonyl carbon. This results in the alpha carbon becoming electron deficient and forming
the enolate carbanion, which is resonance stabilized. Acid catalysis begins with protonation of the
carbonyl’s oxygen, making that oxygen electron rich and favoring enolate formation. For example,
one common catalyst for the aldol reactions is lithium diisopropylamide (LDA), a sterically
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hindered lithium amide base that selectively removes the proton from the least hindered side of
the carbonyl under kinetic control (–78°C in THF).
In nature, the aldol reaction is catalyzed by enzymes called aldolases. For example, class I
aldolases are proposed to undergo enamine catalysis, which involves catalyzing the reactions of
carbonyls with primary or secondary amines via enamine intermediates. In gluconeogenesis, the
biochemical pathway that results in the production of glucose, the aldehyde glyceraldehyde-3phosphate (GAP) and the ketone dihydroxyacetone phosphate (DHAP) are joined together in an
aldol linkage to produce fructose-1,6 -bisphosphate (FBP). This reaction is catalyzed by fructose
bisphosphate aldolase, which contains a lysine residue in its active site that is required for catalytic
activity. The amine group of lysine reacts with the carbonyl of DHAP and forms the imminium
ion, which is in resonance with the enamine intermediate. The DHAP enamine reacts with GAP
forming a carbon-carbon bond. Lastly, the product is protonated and after water reacts with the
imine, FBP is released from the active site of the enzyme and the lysine is free to react again.
Depending on the metabolic and intracellular conditions, aldolases can also catalyze the retro aldol
reaction, in which FBP is split into GAP and DHAP. This process happens in glycolysis when
there is a need to synthesize energy in the form of ATP.
As stated before, a benefit of using aldol chemistry is that the resulting product forms a carboncarbon bond at the site of conjugation. This is an advantage over unstable or reversible methods,
for example hydrazine/oxime ligation or maleimide chemistry. There are two other bioconjugation
techniques that takes advantage of the carbon-carbon bond forming aldol reaction. The Mukaiyama
aldol bioconjugation technique involves reacting an aldehyde with a silyl enol ether, resulting in
the β-hydroxy ketone aldol product.1 The product is limited since it can only be further
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functionalized by either azide-alkyne Huisgen cycloaddition or cross metathesis using a HoveydaGrubbs second generation catalyst. Neither is ideal if the goal is to eliminate possible cell toxicity
due to the use of a metal catalyst. Lewis acids, such as highly volatile TiCl4, are used to catalyze
the reaction. Similarly, the thiazolidinedione aldol bioconjugation technique takes long with
reaction times ranging from 6 hours to two days. Another disadvantage is that this technique only
works with thiazolidinedione ketones. Both of these aldol reactions are limited in their substrate
scope.

In comparison to these two existing bioconjugation methods, advantages of my method include
shorter reaction times ranging from 15 minutes for some peptides to 1 hour for protein
modification, the use of a stable and environmentally friendly catalyst, and a broad substrate scope.
My aldol bioconjugation chemistry is demonstrated on aliphatic small molecule aldehydes and
ketones, glyoxal aldehydes and ketones (peptides and proteins), cyclic ketones, and aromatic
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aldehydes. This organocatalyzed aldol bioconjugation reaction has worked on all aldehydes and
ketones regardless of their structure.

2.2.2 Organocatalyst
Recent literature has illustrated the use of organocatalytic aldol reactions on small molecules in
aqueous medium using proline-derived catalyst. For example, the first experiment that
demonstrated water’s ability to facilitate the aldol reaction in an aqueous environment utilized
nornicotine to form an aldol linkage between acetone and p-chloro-benzaldehyde.2 Similarly,
enantio- and diastereoselectivities of greater than 99% were demonstrated on direct aldol reactions
using water compatible chiral organocatalysts with bulky ligands that created a steric environment
to control selectivity.3 Simply L-proline was used for successful α-thioacetal cross-aldol coupling
with high enantio- and diastereoselectivities.4 These reactions catalyzed by proline and prolinederived organocatalysts proceed through an enamine intermediate similarly to the type I aldolase
enzymes mentioned previously and has demonstrated success in the synthesis of b-hydroxy
aldehydes and ketones.
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Proline has the tendency to from spectator species in the presence of aromatic and electron rich
aldehydes. The iminium species may undergo decarboxylation resulting in the formation of
reversible oxazolidinones and irreversible oxapyrrolizidines.5 The addition of water and excess
proline can alleviate the effect of these parasites.

To my knowledge, the only other bioconjugation method that utilizes an organocatalyst was for
the synthesis of hydrazone and oxime conjugates.6 Aniline and aniline derivatives were used in
the reaction between aldehydes or ketones with hydrazide or aminooxy-derivatized substances.
Aniline is a successful catalyst because its nucleophilic amine adds quickly to the carbonyl and
because it is a good leaving group with its amine’s lone pair electrons being delocalized into the
aromatic ring.7 The use of aniline as an organocatalyst allows the conjugation that typically
proceeds at reaction pH 4-5 to successfully conjugate the molecules at pH 7. However, the toxicity
and carcinogenicity of aniline limits its use as a catalyst in a cellular environment. High
concentrations of aniline can cause erythrocyte toxicity; this includes a multitude of complications
not limited to methemoglobinemia, glutathione depletion, blood instability and decreased
circulation, as well as changes to the membrane cytoskeletal.8 Hemolytic anemia, where healthy
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red blood cells are prematurely destroyed and removed from the body, is also linked to high
concentrations of aniline.9 Similarly, liver toxicity was demonstrated on hepatocytes after
increased oxidative stress and apoptosis was observed following exposure to aniline and its
metabolites.10 The use of aniline as an organocatalyst can interfere with bioconjugation studies
and residual catalysts in the synthesis of conjugates can be detrimental when used as treatments in
a cellular environment.

2.3 Results and Discussion
2.3.1 Phenylalanine Aldehyde Synthesis

A molecule containing one amino acid and an aldehyde, phenylalanine aldehyde, was created to
conduct an initial model study and test whether the proposed method was applicable to molecules
containing amino acids. In step 1 of our synthesis scheme, the methyl ester derivative intermediate
was

created

by

combining

2-Formylpheoxyacetic

acid

(2-FPA

acid),

N,

N'-

Dicyclohexylcarbodiimide (DCC) and N-Hydroxysuccinimide (NHS). 2-FPA acid is used as the
source of the aldehyde and also contains a carboxylic acid that will react with NHS to make the
intermediate. DCC is used in the reaction to increase the electrophilicity of the carboxylate group
for the subsequent step, temporarily attaching to the former carboxylate group creating a highly
electrophilic intermediate, making nucleophilic attack by NHS more efficient. NHS is a common
substance used in organic synthesis as an activating reagent for carboxylic acids. The resulting
intermediate is an activated acid containing an ester and a good leaving group; this also prevents
the formation of an imine between the aldehyde and the amine in the next step.
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In the second step, the phenylalanine methyl ester derivative, phenylalanine aldehyde, was
synthesized. The NHS derivative intermediate synthesized in the previous step was reacted with
L-Phenylalanine methyl ester hydrochloride, which serves as the source of the amino acid. N,NDiisopropylethylamine (DIEA) was used as the base. One equivalent of DIEA was used to quench
HCl reaction and the other equivalent was to abstract the proton. The NHS derivative synthesized
in the previous step was reacted with L-Phe-OMe HCl and the product, phenylalanine aldehyde
was confirmed by NMR.
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2.3.2 Phenylalanine Model Studies, Reaction Optimization, and Catalyst Screening

The model reaction was carried out between phenylalanine aldehyde and acetone, a simple ketone,
in DMSO. The ketone substrate scope was expanded to include hydroxyacetone and
cyclohexanone. This method generates a stable carbon-carbon bond between phenylalanine as the
aldehyde and each of the ketones under biologically relevant conditions, in aqueous medium, in a
rapid manner by the use of proline as an organocatalyst.
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In order to confirm that a catalyst was needed to accelerate the reaction, I compared the results of
the proline catalyzed reaction with an uncatalyzed reaction between phenylalanine aldehyde and
hydroxyacetone (Figure 2.6, A). The proline-catalyzed reaction gave the aldol product with a
conversion of 50 % in 7 h whereas no reaction was observed in the absence of the catalyst. These
results highlight the importance of organocatalysts for catalyzing this bioconjugation reaction.
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The evaluation of the reaction conditions using proline revealed quantitative conversion of the
starting aldehyde to the corresponding aldol bioconjugate at neutral pH (~7.5) using common
organic co-solvents (5% dimethylsulfoxide, DMSO) in sodium phosphate buffer (Figure 2.6, B).
The compatibility of the organocatalyzed aldol reaction using DMSO as a co-solvent was
determined for potential applications aimed at the conjugation of larger peptides and proteins. The
solvent system used in chemical reactions of proteins is important for maintaining the
biomolecule’s structure. The addition of alcohols disrupts hydrogen bonds, acids and bases disrupt
salt bridges, and heavy metal salts disrupt salt bridges and disulfide bonds. DMSO can be used to
prevent protein denaturation and preserve the structure of globular proteins, however, increasing
concentrations of DMSO (>10%) and other organic solvents can lead to protein denaturation, so
protein modifications are typically done in an aqueous environment.11 Preserving the structure of
a protein is important for maintaining its function, especially for more complex proteins, such as
enzymes, antibodies, receptors, and carrier molecules, where a change in structure can prevent
binding to a target and prohibit the protein from performing a function. 50% DMSO in buffer was
chosen as the standard to be used for reactions with small molecules and peptides; not all reactants,
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including peptides, were soluble in 100% buffer. Remarkably, the conversion to the aldol
conjugate product increased with the addition of buffer (86%) as compared to solely organic
solvent (DMSO, 50%) in 7 h. The increase in the rate of the organocatalyzed reaction in buffer
might be due to the dual role of water in activating the aldehyde for nucleophilic attack through
hydrogen bonding, and by accelerating the hydrolysis of the iminium ion intermediate formed
between the aldol bioconjugate and the organocatalyst, resulting in the release of the desired
bioconjugate and regeneration of the catalyst.3

Optimized reaction conditions were obtained by further exploration of the reaction conditions such
as loading of the proline catalyst (Figure 2.8, A and B) and temperature (Figure 2.8, C). The
effect of the amount of proline catalyst on the rate of the aldol reaction was analyzed and the
reaction was performed at different catalyst loadings in DMSO and 1:1 DMSO:Buffer. The high
concentrations of proline might be required because of the tendency of proline to form spectator
species.5
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Various amino acids and small peptides were screened as catalysts. These catalysts have been
shown in literature to catalyze the aldol reaction on small molecules. Proline was chosen for further
studies because it was readily available, unlike peptide catalysts which had to be synthesized and
purified.
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We chose 60°C temperature, 25 mM sodium phosphate buffer at pH 7.5 and 100mM proline as
optimized reaction conditions for further peptide studies. This method under these conditions
generates a stable carbon-carbon bond between an aldehyde and a ketone rapidly in aqueous
medium by the use of an organocatalyst.

2.3.3 Site-Selective Incorporation of Aldehydes and Ketones into Peptides

For any new method to have a major impact on the mainstream practice of bioconjugation, it is
important that the method possesses easy-to-implement changes from the existing protocol. The
advantage of our approach is that methods to install a special orthogonal group, such as an
aldehyde or a ketone, onto proteins or biomolecules are very well established.12 Peptide aldehydes
were generated from N-terminus serine containing peptides by sodium periodate (NaIO4)
oxidation. This results in a modification at only the N-terminal serine, creating an aldehyde sitespecifically on the peptide. Once this peptide undergoes the aldol reaction with a ketone, other
reactive side chain functionalities remain unreactive including serine, arginine, and lysine.

The 2-amino alcohol structure exists in proteins and peptides when serine or threonine are at the
N-terminus as well as in hydroxylysine. A 2-amino alcohol undergoes rapid oxidation by periodate
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at pH 7 generating an N-terminal aldehyde.13 Peptides were synthesized with different numbers of
amino acid residues and varying side chain functionalities, all containing N-terminal serine.
Sodium phosphate buffer (50 mM, pH 7) was prepared. Five equivalents of sodium periodate
(NaIO4) was used in relation to pure peptide. Peptide and NaIO4 were weighed in a glass vial with
a stir bar in the dark. The reaction was left to stir at room temperature for 3 h. The reaction was
filtered to remove excess NaIO4 then purified using RP-HPLC. Peptide NH2-SVF was converted
to aldehyde-VF; the product was confirmed using LCMS and NMR, existing as both the
dehydrated aldehyde form and the hydrated form. Peptides NH2-SGRFA and NH2-SIGSLAK were
converted to peptide-GRFA and peptide-IGSLAK, respectively, and confirmed by LCMS.
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2.3.4 Organocatalyzed Aldol Reaction of Peptide Aldehydes

The bioconjugation reaction of the simplest ketone, acetone, was reacted with aldehyde-VF. This
example was the first illustration of a successful conjugation between the peptide aldehydes and a
ketone.
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Next, various amino acids and peptides were screened for catalyzing the bioconjugation reaction
of aldehyde-VF (the peptide aldehyde) with hydroxyacetone, the ketone of choice, to obtain the
optimized catalyst for bioconjugation. These studies showed that different types of amino acid
derived organocatalysts can be synthesized and tuned for catalyzing a variety of bioconjugation
reactions with high efficiency and selectivity. Although high conversion to aldol-bioconjugate was
observed with some peptide-based catalysts proline was chosen for further studies because it was
readily available and did not have to be synthesized and purified.

The high substrate scope and chemoselective nature of the organocatalyzed bioconjugation
reaction was determined by carrying out the reaction of hydroxyacetone with the three different
peptide aldehydes containing various other reactive side chain functionalities. I synthesized the
peptides, all having a serine residue at the N-terminus, using SPPS then purified the peptides using
HPLC. The peptides were then reacted with NaIO4 and purified again to obtain the final peptide
aldehyde product. The peptide aldehydes were each reacted with hydroxyacetone in the presence
of proline as the organocatalyst. Once these peptides undergo the aldol reaction with a ketone,
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other reactive side chain functionalities remain unreactive including serine, arginine, and lysine.
These results highlight the fast reaction kinetics of the proline-catalyzed bioconjugation reaction
at neutral pH 7.5 and its high chemoselective nature. The reaction was kept in the heated shaker at
60 °C for 15-30 mins. The progress of the reaction was monitored by injecting the sample into the
HPLC after regular intervals of time. The peptide aldol product was analyzed by MS and NMR.
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2.3.5 Macrocyclic Peptide Imine Formation

When lysine is present in the peptide, self-condensation of aldehyde-IGSLAK occurs, resulting in
the formation of a macrocyclic imine.

However, reaction of this macrocyclic imine with

hydroxyacetone ultimately leads to the desired aldol bioconjugate presumably due to the high rate
of transamination reaction of the imine with proline catalyst.14 The reaction progress was
monitored by injecting samples into the HPLC after regular time intervals. The aldol bioconjugate
was analyzed by MS and NMR.
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2.3.6 Bioconjugate Stability
The aldol bioconjugate’s stability was assessed towards acids and bases (with pH range 4.3-10.3)
both at room temperature and at 37 °C. Next, we wanted to test the stability of the aldol product
in the presence of an enzyme that is abundant in our body, such as fructose-bisphosphate aldolase
(aldolase), for up to 4 days. As expected, incubation of IGSLAK for 24h at pH 4.3, 7.3, and 10.3
at both room temperature and 37 °C leads to no detectable degradation. Notably, IGSLAK was
also found to be stable toward the retro-aldol reaction catalyzed by aldolases, which are highly
abundant in nature. The stability of the aldol bioconjugate toward aldolases is presumably due to
the enzyme’s high substrate specificity.15 Although aldolase successfully splits fructose 1,6bisphosphate into dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate, this
enzyme does not reverse the carbon-carbon bond formed in the aldol product through our method,
proving this product is stable to varying pH levels as well as in the presence of the aldolase enzyme.
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2.4 Conclusion
A simple amino acid aldehyde, phenylalanine aldehyde, was used for the optimization of the
reaction conditions and for the exploration of the substrate scope. The model reaction was carried
out between phenylalanine aldehyde and acetone, a simple ketone, in DMSO. Proline was used as
an initial catalyst because of its ability form an imminium ion with the ketone followed by
rearrangement to an enamine. The enamine then carries out nucleophilic attack on the electrophilic
aldehyde that is activated by H-bonding interactions with the catalyst. For further studies, I utilized
hydroxyacetone as the ketone, which contains a hydroxyl group that can be easily functionalized
with other moieties, such as drugs, PEG groups, etc. Additionally, the reaction was done with
cyclohexanone as a ketone substrate broadening the ketone substrate scope of this methodology to
include cyclic ketones. The conversion of the starting materials to the corresponding aldol
bioconjugate was monitored by HPLC and the resulting conjugated product was confirmed by
NMR.
Here, I have demonstrated an ideal bioconjugation reaction that is rapid, compatible with
physiological conditions, and irreversible with a covalent linkage that is strong and inert to
biological conditions. This reaction is chemoselective, resulting only in a reaction between the
aldehyde and the ketone in the presence of various reactive function groups naturally present on
peptides. There is a vast and diverse substrate scope, which is an advantage over other aldol related
methods of bioconjugation. The N-terminal modification and the aldol reaction takes place site
specifically, allowing for controllable conjugation at one particular location on the biomolecule.
In the future, this method can be used to synthesize macrocycles by introducing C-terminal
aldehydes using Weinreb resin and cyclize with an N-terminal ketone that is introduced using PLP.
This work is published in Organic Letters.16
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2.5 Experimental Procedures and Spectral Data
General: All commercial materials (Sigma-Aldrich, Fluka, and Novabiochem) were used without
further purification. All solvents were reagent or HPLC (Fisher) grade. Diethyl ether,
dichloromethane, and N,N-dimethylformamide were obtained from a dry solvent system (passed
through an alumina column) and used without further drying. All reactions were performed under
air in glass vials. HPLC was used to monitor reaction progress.
Materials: Fmoc-amino acids were obtained from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained
from ChemPep Inc. (Wellington, Florida). N,N,N′,N′- Tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky).
4-Dimethylaminopyridine (DMAP) was obtained from Merck KGaA (Darmstadt, Germany). N,NDimethylformamide (DMF) was obtained from Macron Fine Chemicals (Center Valley,
Pennsylvania).

Acetonitrile,

N,N-

diisopropylethylamine

(DIEA),

and

N,N'-

diisopropylcarbodiimide (DIC) were purchased from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts).
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor,
Pennsylvania). Diethyl ether, dichloromethane (DCM), methanol (MeOH), phenylsilane, 1hydroxy-7-azabenzotriazole

(HOAt),

2,4,6-trimethylpyridine,

triphenylphosphine,

tetrahydrofuran (THF), and acetonitrile were obtained from Sigma-Aldrich (St. Louis, Missouri).
Water was purified using a Millipore Milli-Q water purification system.
LC-MS: Peptide compositions were evaluated by high performance liquid chromatography
(HPLC) on an Agilent 1100 series HPLC equipped with a 4.6x150 mm (5μm) C18 column. All
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separations used mobile phases of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic
acid (v/v) in acetonitrile (solvent B). A linear gradient of 0– 80% solvent B in 30 minutes at room
temperature with a flow rate of 1.0 mL min-1 was used. The eluent was monitored by UV
absorbance at 220 nm unless otherwise noted. Mass spectrometry to check reaction mixtures was
performed on an Agilent 1100 Series HPLC with MSD VL mass spectrometer using positive
polarity electrospray ionization (+ESI).

LC-HRMS: This analysis was conducted by Ryan Cohen at Merck facilities. High resolution MS
data were acquired using an Agilent 1290 UHPLC with a 6520 Q-ToF mass spectrometer under
positive polarity electrospray ionization (+ESI) with capillary and fragmentor voltages set to 3.5
kV and 175 V, respectively. The instrument was calibrated prior to data acquisition using Agilent’s
reference standard solution, which provided accurate masses within 5 ppm. A reversed phase,
linear gradient separation was performed at a flow rate of 1.0 mL min-1 on a C18 column (Waters
Acquity UPHLC peptide BEH C18, 1.7 μm particle size, 50 mm x 2.1 mm I.D.) thermostatted at
45°C and gradient from 95% solvent A (0.1% formic acid in water) to 99% solvent B (0.1% formic
acid in acetonitrile) in 4 minutes, followed by 1 minute re-equilibration.
NMR. This analysis was conducted by Ryan Cohen at Merck facilities. Spectral data were
acquired at 25 °C in DMSO-d6 using an Agilent DD2 spectrometer (either 600 MHz or 500 MHz)
equipped with a 3-mm helium triple resonance (HCN) cryoprobe. 1H NMR chemical shifts were
referenced to residual DMSO-d5 at 2.50 ppm, and proton signals were reported as follows:
chemical shifts (1H) in ppm (multiplicity, coupling constants, J in Hz, and integration). Multiplicity
was reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of doublets (dd),
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doublet of triplets (td), triplet (t) and multiplet (m). 13C NMR spectra were proton decoupled, and
chemical shifts (13C in ppm) were referenced to DMSO-d6 at 39.52 ppm. 2D NMR spectra were
acquired to further confirm structures and assign proton and carbon signals. Gradient COSY,
gradient TOCSY (80 ms mixing time), gradient ROESY (250 ms mixing time), gradient
multiplicity-edited HSQC (1JCH optimization set to 145 Hz), and gradient HMBC (nJCH
optimization set to 8 Hz) experiments were performed.
Semi-Preparative HPLC. A Beckman Coulter System Gold instrument was used for compound
purification. The instrument was equipped with a 168-diode array detector and a 125P solvent
module. Separations were performed at ambient temperature with a 10 mm x 150 mm (5

m

particle size) C-18 reversed phase column using an eluent of 0.1% formic acid (v/v) in water
(solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–80%
solvent B over 30 min with a flow rate of 3.0 mL min-1 was employed. The eluent was monitored
by absorbance at 220 and 254 nm unless otherwise noted.
Analytical HPLC. Analytical HPLC was performed on an Agilent 1100 series HPLC equipped
with a 4.6 mm x 150 mm (3 µm particle size) C-18 reversed phase column. All separations used a
mobile phase of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic acid (v/v) in
acetonitrile (solvent B). A linear gradient of 0–80% solvent B in 30 mins at room temperature with
a flow rate of 1.0 mL min-1 was used. The eluent was monitored by absorbance at 220 nm unless
otherwise noted.
LC-MS conditions for reaction monitoring. Mass spectrometry to check reaction mixtures was
performed using an Agilent 1100 series MSD VL in positive polarity electrospray ionization
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(+ESI). This instrument was paired with an Agilent 1100 series HPLC using the previous analytical
HPLC conditions.
High resolution LC-MS conditions for purified peptides. This analysis was conducted by Ryan
Cohen at Merck facilities. Analyses were performed on an ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QToF Premier, Waters) with electrospray ionization (ESI) in positive mode using Mass lynx
software (V4.1). 5 μL of the sample was injected onto a C4 column (WIDEPORE C4 200 Å, LC
Column 50 x 2.1 mm) Phenomenex AerisTM 3.6 μm with a 200 μL/min flow rate of mobile phase
of solution A (95 % H2O, 5% acetonitrile and 0.1% formic acid) and solution B (95% acetonitrile,
5% H2O, and 0.1% formic acid) beginning (gradient time- 0 min 10% B; 5 min 28% B; 20 min
38% B; 22 min 100% B). Capillary voltage was set at 3.0 kV, the sample cone voltage was 50 V,
and the extraction cone was 4.0 V. The source and desolvation temperature were maintained at 95
and 300 °C, respectively, with the desolvation gas flow at 400 L/h. The Time of Flight Mass
Spectrometry (TOF/MS) scan was 1 s long from 100 to 3200 m/z with an 0.02 s inter-scan delay
using extended dynamic range acquisition and centroid data format. The lock mass was used to
correct instrument accuracy with a 0.5 μM solution of HP 1221 (Agilent part number G196985003). Ion source parameters such as the source temperature (gas and sample cone), mobile phase
flow rate, and cone voltage were fixed throughout the study.
Fmoc Solid-Phase Peptide Synthesis.17 Peptides were synthesized manually on a 0.25 mm scale
using Rink amide resins. The Fmoc group was deprotected using 20% piperidine–DMF for 20 min
to obtain a deprotected peptide resin. Fmoc-protected amino acids (1.25 mm) were sequentially
coupled on the resin using HBTU (1.25 mm) and DIEA (1.25 mm) for 2 h at room temperature.
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Peptides were synthesized using standard protocols. The peptide was cleaved from the resin using
a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 h. The resin was
removed by filtration and the resulting solution was concentrated. The oily residue was triturated
with diethyl ether to obtain a white suspension. The resulting solid was purified by semipreparative HPLC.
2.5.1 General Procedure for Phenylalanine Aldehyde Synthesis

2-FPA Acid, NHS, and DCC were dissolved in 15mL. The reaction was stirred at room
temperature for 3 hours and monitored by TLC, then filtered under vacuum, recrystallized, and
dried overnight. The product, NHS intermediate, was analyzed by LCMS and the desired mass of
277 g/mol was observed. The NHS derivative (Formylphenoxy NHS ester) synthesized in the
previous step was reacted with L-Phe-OMe HCl using dry DMF (2.5mL) as a solvent. DIEA was
added and the reaction proceeded for 4 hours then purified via normal phase column
chromatography. The dried product was analyzed via LCMS. The product, phenylalanine aldehyde
(mass 341g/mol) was confirmed by NMR.

1

H NMR (600 MHz, DMSO-d6) δ 10.42 (s, 1H), 7.74 (dd, J = 7.7, 1.8

Hz, 1H), 7.69 (ddd, J = 8.9, 7.3, 1.9 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H),
7.18 (t, J = 7.5 Hz, 1H), 5.55 (s, 2H), 2.83 (s, 4H).

13

C NMR (151

MHz, DMSO-d6) δ 188.8, 169.9, 165.2, 159.3, 136.2, 127.9, 124.8,
122.2, 114.1, 63.7, 25.5.
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1

H NMR (600 MHz, DMSO-d6) δ 10.40 (s, 1H), 8.59 (d, J = 8.1 Hz,

1H), 7.74 (dd, J = 7.7, 1.9 Hz, 1H), 7.59 (ddd, J = 8.8, 7.3, 1.9 Hz,
1H), 7.32 – 7.23 (m, 2H), 7.23 – 7.18 (om, 3H), 7.12 (t, J= 7.5 Hz,
1H), 6.98 (d, J= 8.4 Hz, 1H), 4.70 (d, J= 14.9 Hz, 1H), 4.63 (d, J =
14.9 Hz, 1H), 4.63 – 4.53 (om, 1H), 3.64 (s, 3H), 3.13 (dd, J = 13.8,
5.1 Hz, 1H), 3.00 (dd, J = 13.8, 9.8 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 189.7, 171.6,
167.4, 159.7, 137.1, 136.1, 129.1, 128.2, 128.1, 126.6, 124.4, 121.4, 113.6, 67.0, 53.2, 52.0, 36.3.

2.5.2 Organocatalyzed Aldol Reaction of Phenylalanine Aldehyde
Phenylalanine Aldehyde-Acetone Aldol Reaction
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To phenylalanine aldehyde (7 mM) in DMSO or buffer (400 µL of 100 mM sodium phosphate,
pH 7.5) was added proline (100 mM) and acetone (84 mM), and the reaction was incubated at 60
°C for 15 min on a heated shaker. The reaction progress was monitored at regular intervals by
LCMS. The phenylalanine aldol product was analyzed by NMR.
Phenylalanine Aldehyde-Hydroxyacetone Aldol Reaction

To phenylalanine aldehyde (7 mM) in DMSO or buffer (400 µL of 100 mM sodium phosphate,
pH 7.5) was added proline (100 mM) and hydroxyacetone (84 mM), and the reaction was incubated
at 60 °C for 15 min on a heated shaker. Reaction progress was monitored at regular intervals by
LCMS. The phenylalanine aldol product was analyzed by MS and NMR.
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1

H NMR (500 MHz, DMSO-d6) δ 8.37 (d, J = 7.9 Hz, 1H),

7.44 (d, J = 7.6 Hz, 1H), 7.32-7.11 (om, 6H), 6.96 (t, J = 7.5
Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 5.34-5.25 (om, 2H), 4.98
(d, J = 6.9 Hz, 1H), 4.64-4.55 (m, 1H), 4.53-4.48 (m, 2H),
4.15- 4.11 (m, 1H), 3.62 (s, 3H), 3.17-2.89 (m, 2H), 2.17 (s, 3H). 13C NMR (125 MHz, DMSOd6) δ 211.4, 171.5, 167.7, 154.4, 137.0, 130.7 129.0, 128.2, 127.9, 127.7, 126.5, 120.5, 111.0,
79.2, 68.2, 66.5, 53.2, 52.0, 36.4, 26.7.
Note: NMR spectra shows a mixture of 4 diastereomers at a ratio of ca. 0.15 : 0.22 : 0.26: 0.37
based on the 13C integration for the acetyl group at 26.7 ppm. Only the spectral data for the largest
diastereomer are reported.
2.5.3 Optimization of reaction conditions for aldol bioconjugation
Phenylalanine aldehyde (7 mM) was used to optimize reaction conditions and to explore substrate
scope with different ketones (84 mM), including acetone, hydroxyacetone, and cyclohexanone
using proline (20 mM ) in 1:1 DMSO : 25 mM sodium phosphate buffer (pH 7.5) at 37 °C.
Effect of the loading of proline catalyst on the rate of aldol reaction in DMSO. Reaction
Conditions: phenylalanine aldehyde (7 mM), hydroxyacetone (84 mM), proline (20 mM, 50mM,
and 100 mM) in DMSO at 37 °C.
Effect of the loading of proline catalyst on the rate of aldol reaction in DMSO:Buffer mixture.
Reaction conditions: phenylalanine aldehyde (7mM), hydroxyacetone (84 mM), proline (20 mM,
50 mM, and 100 mM) in 1:1 DMSO : 25 mM sodium phosphate buffer (pH 7.5) at 37 °C.
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Temperature studies with phenylalanine and hydroxyacetone were conducted. Reaction
conditions: phenylalanine aldehyde (7mM), hydroxyacetone (84 mM), and proline (20 mM) in
DMSO at different temperatures. Conversion was determined by analyzing the samples after 3h
and 5h using HPLC.
2.5.4 General procedure for the synthesis of peptide aldehydes
To peptides with serine at the N-terminus (1 eq.) in 50 mM sodium phosphate buffer (pH 7.5) was
added sodium periodate (5 eq.), and the reaction was stirred at room temperature for 3 h. Unreacted
sodium periodate was removed by filtration, and the resulting peptide aldehyde was purified by
HPLC. The pure peptide aldehydes were analyzed by MS and NMR.
1

H NMR (600 MHz, DMSO-d6) δ 9.29 (s,

1H), 8.53 (d, J = 8.9 Hz, 1H), 8.17 (d, J =
8.4 Hz, 1H), 7.34 (br s, 2H), 7.25-7.18 (om,
4H), 7.17-7.13 (om, 1H), 4.49-4.41 (m, 1H), 4.12 (dd, J = 9.2, 6.4 Hz, 1H), 2.97 (dd, J = 13.8, 5.2
Hz, 1H), 2.77 (dd, J = 13.8, 9.2 Hz, 1H), 1.95-1.88 (m, 1H), 0.73 (d, J = 6.7 Hz, 3H), 0.72 (d, J =
6.7 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 189.0, 172.6, 169.6, 160.2, 137.8, 129.1, 128.0,
126.2, 58.2, 53.7, 37.6, 30.5, 19.0, 18.0.
Note: NMR spectra in DMSO-d6 shows a mixture of the aldehyde and its hydrated form at a molar
ratio of ca. 0.14 : 0.86, respectively. The NMR data above are of the aldehyde.
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2.5.5 Organocatalyzed Aldol Reaction of Peptide Aldehydes with Hydroxyacetone

Aldehyde-VF and Acetone Aldol Reaction
To a peptide aldehyde (9-11) (7 mM) in 400 μL 25 mM sodium phosphate buffer, pH 7.5 was
added proline (100 mM) and ketone, acetone or hydroxyacetone (84 mM), and the reaction was
kept in the heated shaker at 60 °C for 15-30 mins. The progress of the reaction was monitored by
LCMS at regular intervals of time. The peptide aldol product was analyzed by MS and NMR.
1

H NMR aldehyde-VF and acetone (600 MHz, DMSO-d6) δ

8.15 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 9.1 Hz, 1H), 7.35 (s, 1H),
7.26-7.21 (om, 4H), 7.20-7.15 (m, 1H), 7.02 (s, 1H), 5.88 (d, J
= 6.0 Hz, 1H), 4.48-4.43 (m, 1H), 4.28 (ddd, J = 8.6, 6.0, 3.9
Hz, 1H), 4.15 (dd, J = 9.1, 6.2 Hz, 1H), 2.99 (dd, J = 13.8, 5.2 Hz, 1H), 2.81-2.71 (om, 2H), 2.60
(dd, J = 16.2, 8.7 Hz, 1H), 2.11 (s, 3H), 1.99-1.89 (m, 1H), 0.76 (d, J = 6.8 Hz, 3H), 0.73 (d, J =
6.8 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ 206.2, 172.8, 172.7, 170.2, 137.8, 129.0, 128.0,
126.1, 67.4, 57.2, 53.6, 47.8, 37.5, 30.8, 30.2, 19.0, 17.7.
Peptide-aldehydes and Hydroxyacetone Aldol Reaction
1

H NMR aldehyde-FV and hydroxyacetone (600 MHz, DMSO-

d6) δ 7.98 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 8.9 Hz, 1H), 7.29-7.16
(om, 6H), 7.06 (s, 1H), 5.78-5.73 (m, 1H), 5.50-5.46 (m, 1H),
4.46-4.11 (om, 4H), 3.03 (dd, J = 13.8, 5.2 Hz, 1H), 2.76 (dd, J =
13.8, 9.2 Hz, 1H), 2.18 (s, 3H), m (2.01-1.94, 1H), 0.73 (d, J = 6.8 Hz, 3H), 0.68 (d, J = 6.8 Hz,
3H).
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2.5.6 Macrocyclic Peptide Imine Formation

This analysis was performed by Ryan Cohen. The peptide containing free side-chain lysine can
undergo intramolecular reaction with the N-terminal aldehyde leading to the formation of imine.
NMR spectra were consistent with the below structure where by the aldehyde cyclized through an
intramolecular reaction with the Lys residue resulting in a trans imine. This structure was
determined by the presence of the imine proton at 7.66 ppm attached to a carbon at 156.4 ppm,
which was observed in the HSQC spectrum. The carbon at 156.4 ppm would be too upfield for the
aldehyde structure. Furthermore, the HMBC spectrum shows correlations from the imine proton
to both Lys and Ile residues. Finally, the trans configuration was determined by a strong ROE from
the ε protons of Lys to the imine proton, and this determination was further supported by the
downfield carbon chemical shift of the ε carbon at 59.4 ppm (e.g., cis would be expected at approx.
55 ppm).

Reprinted with permission from Howard, T. S.; Cohen, R. D.; Nwajiobi, O.; Muneeswaran, Z. P.; Sim, Y. E.; Lahankar, N. N.; Yeh, J. T.-H.; Raj, M. Org. Lett., 2018,
20 (17), 5344–5347. Copyright 2018 American Chemical Society.
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1

H and 13C NMR data for Aldehyde-IGSLAK Macrocyclic Imine

1

H chemical shifta

1

H multiplicityb and

13

C chemical

residue

position

(ppm)

coupling constant (Hz)

shifta (ppm)

Ser-1

CH

7.66

br s

156.4

(imine)
Ser-1

CO

N/A

N/A

162.5

Ile-2

CO

N/A

N/A

171.1

Ile-2

C2H

4.27

dd, J = 8.8, 7.5

56.7

Ile-2

C3H

1.79

m

36.6

Ile-2

C3’H3

0.83

om

15.3

Ile-2

C4H2

1.44 / 1.03

om / ddd, J = 15.7, 13.9, 7.6

24.4

Ile-2

C5H3

0.82

om

10.9

Ile-2

NH

7.91

d, J = 8.5

N/A

Gly-3

CO

N/A

N/A

169.0

Gly-3

CαH2

3.90 / 3.55

dd, J = 16.5, 6.7 / dd, J = 16.5,

42.6

4.7
Gly-3

NH

8.57

t, J = 5.5

N/A

Ser-4

Co

N/A

N/A

170.0

Ser-4

CαH

4.19

om

55.3

Ser-4

CβH2

3.63 / 3.55

om, om

61.1

Ser-4

OH

5.00

t, J = 5.2

N/A
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Ser-4

NH

7.87

d, J = 6.9

N/A

Leu-5

CO

N/A

N/A

171.8

Leu-5

C2H

4.20

om

51.4

Leu-5

C3H2

1.45 / 1.54

om / om

39.9

Leu-5

C4H

1.63

om

24.1

Leu-5

C5H3

0.87

d, J = 6.6

23.1

Leu-5

C5’H3

0.83

om

21.4

Leu-5

NH

7.85

d, J = 6.6

N/A

Ala-6

CO

N/A

N/A

171.9

Ala-6

CαH

4.16

om

48.5

Ala-6

CβH3

1.17

d, J = 7.1

17.2

Ala-6

NH

7.70

d, J = 6.7

N/A

Lys-7

CONH2

7.15 / 6.99

s/s

173.6

Lys-7

CαH

4.15

om

52.0

Lys-7

CβH2

1.62

om

31.4

Lys-7

CγH2

1.27 / 1.23

om / om

22.7

Lys-7

CδH2

1.61 / 1.53

om / om

28.9

Lys-7

CεH2

3.66 / 3.39

om / om

59.4

Lys-7

NH

7.63

d, J = 8.2

N/A

a: 1

H and 13C signals referenced to DMSO-d5/-d6 solvent signals at 2.50 and 39.52 ppm,
respectively b: s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of doublets
of doublets, t = triplet, br s
Reprinted with permission from Howard, T. S.; Cohen, R. D.; Nwajiobi, O.; Muneeswaran, Z. P.; Sim, Y. E.; Lahankar, N. N.; Yeh, J. T.-H.; Raj, M. Org. Lett., 2018,
20 (17), 5344–5347. Copyright 2018 American Chemical Society.
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Chapter 3: Aldol Reaction for Protein Bioconjugation
3.1 Chapter Objectives

There is an increasing need for chemical strategies that can effectively attach synthetic molecules
site specifically to proteins. In Chapter 2, I have demonstrated this aldol bioconjugation method
works on a single amino acid as well as a small peptide. Next, I focused my efforts on
demonstrating this methodology’s applicability on larger biomolecules, such as proteins, and even
more complex biomolecules, such as antibodies. A range of proteins with different functionalities
will be used, including myoglobin, G110 single domain antibody, and α-lactalbumin. These
proteins will be conjugated to small molecules, peptides, FITC, biotin, and a maleimide dye. Also,
cellular studies will demonstrate the applicability of the method to work successfully in a
biological environment without negatively affecting the protein’s structure or function.

In this chapter the ability of these amino-acid-based organocatalysts to catalyze the bioconjugation
reaction efficiently, independent of the nature of proteins as an electrophile or nucleophile, will
also be explored. This expands the substrate scope of my method by not limiting the residue present
at the N-terminus of proteins. Using existing methods, proteins that naturally contain a N-terminal
glycine can be converted to an aldehyde while those that contain a plethora of other N-terminal
amino acids can easily be converted to ketones.
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3.2 Introduction
3.2.1 Important Considerations for Protein Modifications

Each amino acid differs in their side chain, which gives each of them unique characteristics. These
amino acids are linked via amide bonds to make polypeptides and proteins. Once the side chains
of the amino acids interact the biomolecule assumes a particular shape or conformation. Amino
acids interact through main chain hydrogen bonding to form a-helix and b sheet secondary
structures. The side chains interact through multiple interactions, such as disulfide bridges,
hydrophobic interactions, hydrogen bonds, and ionic interactions, to form the tertiary structure.
These associations cause the protein to fold upon itself into a more compact structure, with polar
amino acids having a tendency to be solvent exposed and nonpolar amino acids buried inside
forming a hydrophobic core.

Reaction conditions influence interactions within biomolecules. For example, biomolecules can
be sensitive to prolonged exposure to acidic conditions resulting in damage.1 Acidic (those with
carboxyl groups) or basic (those with amine groups) amino acids’ ionization can be changed
depending on the solution’s pH, which would result in disruption of ionic interactions within the
protein. A protein’s native or active structure may also be disrupted by an increase in heat, which
would cause weak nonbonding interactions, such as hydrogen bonds, to break and denature the
protein. The solvent system used in chemical reactions of proteins is also important for maintaining
its structure, where a change in conformation can prevent binding to a target and prohibit the
protein from performing a function. However, limiting quantities of organic stabilizers such as
DMSO and TFE can be used to prevent protein denaturation and to preserve the structure of
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globular proteins.2,3 In order to maintain the structure and function of the proteins we chose to
modify, the reactions were done under biological conditions such as neutral pH (7.5), a temperature
of 37 °C, and in aqueous medium. DMSO was used for insoluble ketones and other substrates but
is not necessary with reactants that are water soluble.

3.2.2 Protein Modification Methods for N-terminal aldehydes and ketones
Rapoport’s Salt (RS)

The first method explored to modify myoglobin protein to one containing a N-terminal aldehyde
was by using N-methylpyridinium-4-carboxaldehyde benzenesulfonate, or Rapoport’s Salt (RS).
Rapoport’s salt acts as a transamination reagent, allowing for site-selective modification of
peptides and proteins by conversion of the N-terminal amine to a non-native aldehyde or ketone.
In the case of myoglobin, the N-terminal glycine amino acid is converted to an N-terminal aldehyde
using RS. According to literature, peptide screening studies showed that treatment with RS resulted
in over 80% transamination.4 The reaction yield varies depending on the amino acid residue at the
N-terminal position, however, the side chain of that residue does not directly participate in the
transamination mechanism. The steric bulk of RS most likely contributes to its decreased yield as
well as inability to react with lysine and other amines.4 The reaction produced the desired product,
however, protein aggregation complicated purification methods so Pyrdoxial-5-Phosphate was
used to modify myoglobin to its aldehyde derivative.
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Pyridoxal-5-Phosphate (PLP)

Pyridoxal-5-Phosphate is a biological coenzyme in transamination reactions, especially those
reactions involved in amino acid metabolism.5 PLP-dependent enzymes are recognized as drug
targets and are known to be involved in other important biochemical pathways, such as the
synthesis of nucleotides and lipid metabolism.6a,6b Enzyme cofactors are small organic molecules
that assist enzymes in doing a particular chemical job. PLP contains a reactive aldehyde group that
forms a reversible imine with the ε-amino group of lysine in the enzyme or with amino acids or
similar primary amine containing compounds.

PLP has been explored as a transamination reagent to site-specific incorporate of an aldehyde or
ketone on to the N-terminus of a protein to be used for bioconjugation with alkoxyamine to form
an oxime linkage.7 This PLP-mediated transamination reaction works on most of the twenty

84

natural amino acids, excluding histidine, lysine, tryptophan, and proline. Proline, which is a
secondary amine, undergoes ring opening then forms a covalent PLP adduct and lysine forms a
cyclic enamine, which can further undergo aldol reaction with PLP. Histidine and tryptophan
undergo Pictet-Spengler addition of PLP.8 For amino acids with high to intermediate conversions,
exposure to aqueous solvent or incorporation of spacers at the N-terminus of proteins can increase
reactivity.

3.3 Results and Discussions
3.3.1 Native Myoglobin Analysis

The first protein used in this experiment was horse heart myoglobin, which contains a N-terminal
glycine residue. As stated before, an N-terminal glycine residue can be converted into an aldehyde
by various methods, including the transamination reagent pyridoxal-5-phosphate. This aldehyde
can then be conjugated to a ketone using my aldol bioconjugation methodology. A heme prosthetic
group, an iron-containing porphyrin ring, sits noncovalently in the protein’s hydrophobic crevice
and this unit is responsible for myoglobin’s biological activity. Detection of the heme group
following modification confirms that the tertiary structure of myoglobin remained unaffected by
this methodology. The iron in myoglobin binds oxygen, which is stabilized by distal and proximal
histidine residues, and transports oxygen to the muscle tissue.
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3.3.2 Myoglobin Aldehyde Synthesis

PLP was used in this project to transform both peptides and proteins into aldehydes and ketones.
When used for aldol bioconjugation, the PLP reagent was removed following reaction using RPHPLC to prevent the aldehyde of the PLP molecule from quenching the keto-reactive group in the
reaction, which would considerably lower the concentration of reactive ketone. Myoglobin, a
protein with glycine at the N-terminus, was reacted with PLP in 25 mM sodium phosphate buffer
(pH 6.5) and incubated at 37 °C for 4–20 h. These conditions represent the standard conditions for
most proteins and can be used as a starting point for optimization for protein targets. Concentration
of PLP, temperature, pH, and incubation time are variable; reaction time can be decreased with the
use of higher concentrations of PLP (up to 100 mM). However, high temperatures and drastic
changes in pH should be carefully considered in order to maintain the native conformation of the
protein.
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3.3.3 Myoglobin Aldol Model Reactions, Structure Confirmation, and Control Reactions

Myoglobin aldehyde was reacted with a small molecule ketone, hydroxyacetone, at 37°C in buffer
using proline as the organocatalyst. The two reactants formed the bioconjugate product within 30
minutes with an 80% conversion as determined by LCMS. A protein’s native structure is essential
for its biological activity so developing a method with mild reaction conditions was of priority.
Myoglobin is a single chain globular protein consisting of 153 amino acids and its highly compact
structure consists of eight alpha helical secondary structures. Circular dichroism (CD) spectra were
obtained for both modified and unmodified myoglobin protein to analyze if the modification
reaction would disrupt the secondary structure of myoglobin. CD spectra between 260 nm and 180
nm can be analyzed for the different secondary structural types, which are alpha helix, beta sheet,
and random coil.9
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A known characteristic of myoglobin is that the detection of the heme group shows a strong
absorbance peak in the visible spectrum at 409 nm. The UV-Vis absorbance of the heme group in
the modified myoglobin was compared with that of the native myoglobin to confirm that the
tertiary structure of myoglobin remained unchanged by the conjugation. The analysis of the
resulting myoglobin bioconjugate with hydroxyacetone using CD and UV showed that the
structure of the modified myoglobin protein remained intact after the reaction.
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Two control reactions were performed. The first control reaction was between hydroxyacetone and
unmodified myoglobin, which did not contain the aldehyde handle. There was no bioconjugation
product observed after 24 h, which illustrates the chemoselectivity and specificity of this reaction
and confirming it only happens between the aldehyde and the ketone. The second reaction was in
the absence of organocatalyst, which also showed no bioconjugation product after 24 h. This result
confirms that an organocatalyst in needed for the reaction to proceed.

3.3.4 Protein-Peptide, Protein-FITC, and Protein-Biotin Bioconjugation

The next step in the development of this bioconjugation method was to conjugate two
biomolecules, a peptide and a protein, together. For this, I utilized the same aldehyde, which was
myoglobin transformed via reaction with PLP. The ketones used were synthesized by converting
peptides containing N-terminal alanine resides into peptide ketones also using the transamination
reagent, PLP. Before performing the reaction using myoglobin, a small molecule aldehyde,
salicylaldehyde, was used for a model reaction.
A catalyst screening of peptide ketone-GIRVF and salicylaldehyde, a small molecule aldehyde,
showed that peptide ketones gave high conversion to the bioconjugate products with O-tBu-Thr
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(86% conversion) as compared to proline (68% conversation). I hypothesize that this could be due
to a steric hinderance introduced between the secondary amine of proline and the incoming peptide
ketone. This can be alleviated by using a primary amine, which is less bulky when reacting with
the incoming peptide ketone. O-tBu-Thr was chosen from a list of known aldolase mimicking
organocatalysts on small molecules.10

Next, two peptides containing N-terminal alanine, NH2-AGIRVF and NH2-AACF, were
synthesized, converted to peptide ketones, ketone-GIRVF and ketone-ACF, then conjugated to
myoglobin aldehyde. The ketones were synthesized from the reaction of the purified peptides with
PLP.
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The desired protein bioconjugation products were successfully synthesized, obtaining 66%
conversion for the myoglobin aldehyde and ketone-GIRVF conjugate and 83% conversion for the
myoglobin aldehyde and ketone-ACF conjugate when using O-tBu-Threonine (O-tBu-Thr) as the
organocatalyst.

In chapter 2, myoglobin-aldehyde was conjugated to small molecule hydroxyacetone and two PLPderived peptide ketones. To further demonstrate the substrate scope of the aldol bioconjugation
method, two additional ketones were conjugated to myoglobin-aldehyde. The next ketone used is
a levulinic acid derivative that was synthesized by forming an amide bond between the nonproteinogenic amino acid, levulinic acid, and benzylamine using traditional coupling reagents
HBTU and DIEA in DMF. The levulinic acid was modified with benzylamine to increase the
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aromaticity of the compound and improve its detection by HPLC, which is an UV absorbance
detector. The product was confirmed by NMR.
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Next, the levulinic acid derivative was successfully conjugated to myoglobin aldehyde using otBu-Thr as the organocatalyst. This modification, conjugation, and analysis were done by Ogonna
Nwajiobi at Auburn University. The aldol bioconjugate formed underwent further dehydration to
the more stable α,β-unsaturated carbonyl. An intramolecular aldol reaction took place next,
followed by an additional dehydration step forming a furan ring at the site of conjugation.
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Further, advancing from amino acids and peptide ketones, reaction of myoglobin aldehyde with
FITC and biotin ketones further demonstrated the flexibility of this approach. These two examples
were done by Ogonna Nwajiobi at Auburn University. The FITC ketone was synthesized by first
converting peptide NH2-AKF to ketone-KF using PLP. Next, an amide bond was formed between
the lysine of ketone-KF and FITC using DIEA is DMF, resulting in the formation of FITC-ketone.
FITC-ketone was conjugated to myoglobin aldehyde through the aldol bioconjugation method
using organocatalyst O-tBu-Thr in sodium phosphate buffer at neutral pH and 37°C, forming the
myoglobin-FITC conjugate. Lastly, the biotin ketone was synthesized by the esterification reaction
between D-biotin and N-hydroxysuccinimide (NHS) using HBTU and DIEA in DMF, forming Dbiotin-NHS ester. The lysine of ketone-KF was coupled to D-biotin-NHS ester using DIEA in
DMF, forming biotin-ketone. Biotin-ketone was conjugated to myoglobin aldehyde through the
aldol bioconjugation method using organocatalyst O-tBu-Thr in sodium phosphate buffer at
neutral pH and 37°C, forming the myoglobin-biotin conjugate.
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3.3.5 Role-Reversal: Aldol Conjugation using Protein-Ketones

The roles of the aldehydes and ketones functionalities can be reversed. This allows the aldol
organocatalyzed bioconjugation reaction to work on a range of proteins with different native Nterminal residues. As stated before, the small molecule aldehyde, salicylaldehyde, was used for a
model reaction with peptide ketone-GIRVF.
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This α-lactalbumin protein modification, conjugation, and analysis was done by Ogonna Nwajiobi
at Auburn University. The model protein for this reaction is α-lactalbumin, which is responsible
for regulating lactose production in the milk of most mammalian species.11 It is the most abundant
protein in whey and is an important source of energy for newborns. At neutral pH, it forms a
compact globular structure that is held in tact by four disulfide bonds. This small protein has 123
amino acid residues with a glutamic acid residue at the N-terminus, which was advantageous for
this project since a ketone can easily be generated at the N-terminus.12

102

A ketone functional handle was generated on the terminus and was reacted with 2-pyridine
carboxaldehyde (2-PCA) in the presence of organocatalyst O-tBu-Thr. The aldol bioconjugate
formed underwent further dehydration and formed the more stable α,β-unsaturated enone after
reaction for 1h. 2- PCA is an aromatic aldehyde therefore, this product was formed likely due to
increased stabilization of the resulting double bond by conjugation with the aldehyde’s aromatic
ring.

Next, α-lactalbumin- ketone was conjugated to another biomolecule, peptide aldehyde-VF, in
order to demonstrate the substrate scope of this reaction. The resulting aldol bioconjugate had a
57% conversion in 1h.
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3.4 Conclusion

I note that the ease of utilizing amino acids as catalysts makes them particularly attractive for
routine modification of biomolecules for application in chemical biology, in medicine, and for
generating peptide−polymer conjugates in material science. The broad substrate scope is illustrated
by the plethora of protein conjugation examples presented in this chapter This organocatalyzed
bioconjugation strategy proceeds in aqueous media under mild temperature and pH conditions
while being able to tolerate a wide variety of reactive functional groups and leads to formation of
a stable C−C bond at the site of conjugation while not disrupting the native conformation of the
protein. This method demonstrates excellent selectivity and broad scope for modification of a vast
majority of proteins with different amino acids, both natural and engineered, at the N-terminus by
converting them into either aldehyde or ketone handles.

104

In all the above experiments, a peptide or protein with an electrophilic N-terminal aldehyde was
conjugated to a small molecule containing a nucleophilic ketone, also reported by Spears and
colleagues while our manuscript was under review.13 Uniquely, I report that these roles can be
reversed. The method I developed to modify proteins site selectively works successfully whether
the protein contains the aldehyde or the ketone functional handle. These amino-acid-based
organocatalysts catalyze the bioconjugation reaction efficiently, independent of the nature of
proteins as an electrophile or nucleophile, which has not been demonstrated before with any other
bioconjugation method. Another unique feature is the potential of this method to generate chiral
centers at the site of conjugation, which is of high importance in drug discovery since
stereoselectivity is crucial for the active binding conformation.14 Furthermore, the compatibility
of this reaction with free cysteine groups was utilized for dual labeling of proteins for cellular
imaging. Thus, this method has the potential for synthesizing multiple conjugated biomolecules
for various biophysical studies and drug delivery. This work is published in Organic Letters.15

3.5 Reagents, Experimental Procedures and Spectral Data
General. All commercial materials (Aldrich, Fluka, Nova) were used without further purification.
All solvents were reagent or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2, and
DMF were obtained from a dry solvent system (passed through a column of alumina) and used
without further drying. All reactions were performed under air in round bottom flasks. Yields refer
to chromatographically pure compounds; % yields were obtained by comparison of HPLC peak
areas of products and starting material. HPLC was used to monitor the reaction progress.
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Materials. Fmoc-amino acids were obtained from Nova Biochem (EMD) Millipore Corporation,
Billerica, Massachusetts) and Rink amide, Wang, Chem Matrix and TentaGel resins were obtained
from ChemPrep Inc. (Wellington, Florida). N,N,N′,N′- Tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky).
4-Dimethylaminopyridine (DMAP) was obtained from Merck KGaA (Darmstadt, Germany). N,NDimethylformamide (DMF) was obtained from Macron Fine Chemicals (Center Valley,
Pennsylvania).

Acetonitrile,

N,N-

diisopropylethylamine

(DIEA),

and

N,N'-

diisopropylcarbodiimide (DIC) were purchased from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts).
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor,
Pennsylvania). Diethyl ether, dichloromethane (DCM), methanol (MeOH), phenylsilane, 1hydroxy-7-azabenzotriazole

(HOAt),

2,4,6-trimethylpyridine,

triphenylphosphine,

tetrahydrofuran (THF), and acetonitrile were obtained from Sigma-Aldrich (St. Louis, Missouri).
Water was purified using a Millipore Milli-Q water purification system.

LC-MS: Peptide compositions were evaluated by high performance liquid chromatography
(HPLC) on an Agilent 1100 series HPLC equipped with a 4.6x150 mm (5μm) C18 column. All
separations used mobile phases of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic
acid (v/v) in acetonitrile (solvent B). A linear gradient of 0– 80% solvent B in 30 minutes at room
temperature with a flow rate of 1.0 mL min-1 was used. The eluent was monitored by UV
absorbance at 220 nm unless otherwise noted. Mass spectrometry to check reaction mixtures was
performed on an Agilent 1100 Series HPLC with MSD VL mass spectrometer using positive
polarity electrospray ionization (+ESI).
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LC-HRMS: Analysis was done at Merck facilities at Rahway, NJ by Ryan Cohen. High
resolution MS data were acquired using an Agilent 1290 UHPLC with a 6520 Q-ToF mass
spectrometer under positive polarity electrospray ionization (+ESI) with capillary and fragmentor
voltages set to 3.5 kV and 175 V, respectively. The instrument was calibrated prior to data
acquisition using Agilent’s reference standard solution, which provided accurate masses within 5
ppm. A reversed phase, linear gradient separation was performed at a flow rate of 1.0 mL min-1
on a C18 column (Waters Acquity UPHLC peptide BEH C18, 1.7 μm particle size, 50 mm x 2.1
mm I.D.) thermostatted at 45°C and gradient from 95% solvent A (0.1% formic acid in water) to
99% solvent B (0.1% formic acid in acetonitrile) in 4 minutes, followed by 1 minute reequilibration.

NMR. This analysis was conducted by Ryan Cohen at Merck facilities. Spectral data were
acquired at 25 °C in DMSO-d6 using an Agilent DD2 spectrometer (either 600 MHz or 500 MHz)
equipped with a 3-mm helium triple resonance (HCN) cryoprobe. 1H NMR chemical shifts were
referenced to residual DMSO-d5 at 2.50 ppm, and proton signals were reported as follows:
chemical shifts (dH) in ppm (multiplicity, coupling constants, J in Hz, and integration).
Multiplicity was reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of doublets
(dd), doublet of triplets (td), triplet (t) and multiplet (m). 13C NMR spectra were proton decoupled,
and chemical shifts (dC in ppm) were referenced to DMSO-d6 at 39.52 ppm. 2D NMR spectra
were acquired to further confirm structures and assign proton and carbon signals. Gradient COSY,
gradient TOCSY (80 ms mixing time), gradient ROESY (250 ms mixing time), gradient
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multiplicity-edited HSQC (1JCH optimization set to 145 Hz), and gradient HMBC (nJCH
optimization set to 8 Hz) experiments were performed.

Semi-Preparative HPLC. A Beckman Coulter System Gold instrument was used for compound
purification. The instrument was equipped with a 168-diode array detector and a 125P solvent
module. Separations were performed at ambient temperature with a 10 mm x 150 mm (5 µm
particle size) C-18 reversed phase column using an eluent of 0.1% formic acid (v/v) in water
(solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–80%
solvent B over 30 min with a flow rate of 3.0 mL min-1 was employed. The eluent was monitored
by absorbance at 220 and 254 nm unless otherwise noted.

Analytical HPLC. Analytical HPLC was performed on an Agilent 1100 series HPLC equipped
with a 4.6 mm x 150 mm (3 µm particle size) C-18 reversed phase column. All separations used a
mobile phase of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic acid (v/v) in
acetonitrile (solvent B). A linear gradient of 0–80% solvent B in 30 mins at room temperature with
a flow rate of 1.0 mL min-1 was used. The eluent was monitored by absorbance at 220 nm unless
otherwise noted.

LC-MS conditions for reaction monitoring. Mass spectrometry to check reaction mixtures was
performed using an Agilent 1100 series MSD VL in positive polarity electrospray ionization
(+ESI). This instrument was paired with an Agilent 1100 series HPLC using the previous analytical
HPLC conditions.

108

High resolution LC-MS conditions for myoglobin-GIRVF aldol bioconjugate
Instrument: Agilent 1290 UHPLC with 6520 Q-ToF | Mass Range: m/z 150 to 3200 | Ionization:
(+) ESI | Voltages: capillary = 3.5 kV, fragmentor = 175 V, skimmer = 65 V | Drying Gas: N2 at
300°C | Nebulizer: N2 at 35 L/min | Acquisition Rate: 1 spectra/s | Flow Rate: 0.1 mL/min |
Injection Volume: 15 mL | Mobile Phase: A = 0.1% formic acid in water; B = acetonitrile |
Gradient: 15% B to 50% B in 55 minutes, followed by 5 minute re-equilibration time | Column:
Acquity UPLC Peptide BEH C18, 300Å, 1.7 mm, 1.0 X 150 mm | Column Temp.: 50°C |
Deconvolution using maximum entropy algorithm in Masshunter software.

High resolution LC-MS conditions for all other purified peptides. This analysis was conducted
by Ryan Cohen at Merck facilities. Analyses were performed on an ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QToF Premier, Waters) with electrospray ionization (ESI) in positive mode using Mass lynx
software (V4.1). 5 μL of the sample was injected onto a C4 column (WIDEPORE C4 200 Å, LC
Column 50 x 2.1 mm) Phenomenex AerisTM 3.6 μm with a 200 μL/min flow rate of mobile phase
of solution A (95 % H2O, 5% acetonitrile and 0.1% formic acid) and solution B (95% acetonitrile,
5% H2O, and 0.1% formic acid) beginning (gradient time- 0 min 10% B; 5 min 28% B; 20 min
38% B; 22 min 100% B). Capillary voltage was set at 3.0 kV, the sample cone voltage was 50 V,
and the extraction cone was 4.0 V. The source and desolvation temperature were maintained at 95
and 300 °C, respectively, with the desolvation gas flow at 400 L/h. The Time of Flight Mass
Spectrometry (TOF/MS) scan was 1 s long from 100 to 3200 m/z with an 0.02 s inter-scan delay
using extended dynamic range acquisition and centroid data format. The lock mass was used to
correct instrument accuracy with a 0.5 μM solution of HP 1221 (Agilent part number G1969-
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85003). Ion source parameters such as the source temperature (gas and sample cone), mobile phase
flow rate, and cone voltage were fixed throughout the study.

Fmoc Solid-Phase Peptide Synthesis16 Peptides were synthesized manually on a 0.25 mm scale
using Rink amide resins. The Fmoc group was deprotected using 20% piperidine–DMF for 20 min
to obtain a deprotected peptide resin. Fmoc-protected amino acids (1.25 mm) were sequentially
coupled on the resin using HBTU (1.25 mm) and DIEA (1.25 mm) for 2 h at room temperature.
Peptides were synthesized using standard protocols. The peptide was cleaved from the resin using
a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 h. The resin was
removed by filtration and the resulting solution was concentrated. The oily residue was triturated
with diethyl ether to obtain a white suspension. The resulting solid was purified by semipreparative HPLC.

3.5.1 General Procedure for the Synthesis of Protein Aldehyde
Pyridoxal-5-Phosphate (PLP)7

A protein with glycine at the N-terminus (5mg) was dissolved in 25 mM sodium phosphate buffer
(pH 6.5). A pyridoxal 5-phosphate (PLP) stock solution was prepared and immediately used
because this compound has been reported to degrade in aqueous solution.17 It is typically to make
the PLP stock solution in 10-50 mM phosphate buffer at pH 6.5; this is also the conditions the
transamination reaction will be performed in. Due to the presence of the phosphate group, addition
of PLP to the buffer can alter the pH of the buffer solution. Checking and adjusting the pH to 6.5
using a microelectrode throughout this process is recommended so the solution would not be over
acidic, which could cause the protein to precipitate or even lead to poor conversion. Also, the PLP
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stock solution should be made at two times the desired concentration since it will be added to the
protein solution in a 1:1 volume ratio. Therefore, for a 10 mM PLP transamination reaction, the
following guidelines may be followed to make 1 mL of PLP stock solution at double the desired
concentrated (20 mM): Add 5.3 mg of pyridoxal-5-phosphate monohydrate from Sigma to 1 mL
of 25 mM phosphate buffer, pH 6.5, followed by the addition of 24 μL of 1 M NaOH and brief
vortexing. The PLP stock solution is added to the protein solution in a 1:1 volume ratio. After
combining the protein solution and the PLP stock solution, the final concentration of PLP should
be 10 mM and the concentration of protein should be 10-500 μM. To prepare the sodium phosphate
buffer, 3.1g NaH2PO4 and 10.9g Na2HPO4 were dissolved in 1L diH20. This 0.1M stock solution
has a pH of 7.3-7.5.

Rapoport’s Salt (RS)4
A modified protocol to the one referenced was used.4 For the reaction, 4000 times the
concentration (mM) of RS was used as compared to protein. To prepare the sodium phosphate
buffer, 3.1g NaH2PO4 and 10.9g Na2HPO4 were dissolved in 1L diH20. This 0.1M stock solution
has a pH of 7.3-7.5. Next, 10mL of the stock solution was diluted with 40mL of diH2O to make a
50mL, 25mM solution. 10mg of sodium azide (NaN3) was added to the buffer solution. The pH
was again confirmed to be between 7.3 and 7.5. Next, 5mg of protein was dissolved in 300ul
buffer/sodium azide solution and 323mg RS was dissolved in 300ul buffer/sodium azide solution.
The two were mixed and left on the heated shaker at 37°C at 90rpm. The reactions were removed
after 2.5 hours and frozen, then purified the next day and analyzed by MS.
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3.5.2 General Procedure of Protein Myoglobin Control Reactions
To an unmodified protein myoglobin (0.15 mM) in buffer (sodium phosphate buffer, 25 mM, pH
7.5) was added proline (100 mM) and hydroxyacetone (10 mM) and the reaction was kept in the
heated shaker at 37 °C for 1h 30 min. The progress of the reaction was monitored by injecting the
sample in the LCMS. No aldol product was observed after 1.5 hr and 20hr. To a protein myoglobin
aldehyde (0.15 mM) in buffer (sodium phosphate buffer, 25 mM, pH 7.5) was added
hydroxyacetone (10 mM) and the reaction was kept in the heated shaker at 37 °C for 1h 30 min.
The progress of the reaction was monitored by injecting the sample in LCMS. In the absence of
catalyst, no aldol product was observed after 1.5 hr. No aldol product was observed after 20hr.

3.5.3 General Procedure of the Organocatalyzed Aldol Reaction of Protein Myoglobin Aldehyde
with Hydroxyacetone
To a protein myoglobin aldehyde (0.15 mM) in buffer (sodium phosphate buffer, 25 mM, pH 7.5)
was added proline (100 mM) and hydroxyacetone (10 mM) and the reaction was kept in the shaker
at 37 °C for 1h 30 min. The progress of the reaction was monitored by injecting the sample in
LCMS after regular intervals of time. The reaction was analyzed by ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QTof Premier, Waters).

3.5.4 General Procedure for the Synthesis of Peptide Ketone
Peptides with alanine at the N-terminus was converted to a peptide-ketone using PLP as described
in section 3.5.1.
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3.5.5 General Procedure for the catalyst screening for peptide ketone-GIRVF with Salicylaldehyde
The reaction of peptide ketone-GIRVF (7 mM) with salicylaldehyde (84 mM) was kept for 18 h
at 37 °C in 25 mM sodium phosphate buffer (pH 7.5) and DMSO (3:1). 100mM of each
organocatalyst, proline and O-tBu-Thr were used in the reaction mixture. The conversion was
determined by HPLC.

3.5.6 General procedure of protein myoglobin aldehyde and peptide-ketone conjugate

To a protein myoglobin aldehyde (0.15 mM) in 85 % buffer (sodium phosphate buffer, 25 mM,
pH 7.5) with 15% DMSO in a total volume was added ketone-GIRVF (10 mM) and O-tBu-Thr
(100 mM) as a catalyst. The reaction was kept in the heated shaker at 37 °C for 1h. DMSO was
used for ketone-GIRVF solubility. The reaction was analyzed by Agilent 1290 UHPLC with 6520
Q-ToF.
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To a protein myoglobin aldehyde (0.15 mM) in 85 % buffer (sodium phosphate buffer, 25 mM,
pH 7.5) with 15% DMSO in a total volume of 300 μL solvent was added ketone - ACF (10 mM)
and O-tBu-Thr (100 mM) as a catalyst. The reaction was kept in the heated shaker at 37 °C for 1h.
DMSO was used for ketone-ACF solubility. The reaction was analyzed by ultra-performance LC
system (ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass
spectrometer (Q-Tof Premier, Waters)
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3.5.7 Reaction of Myoglobin Aldehyde with Levulinic Acid Derivative

First the levulinic acid derivative was synthesized in solution by combining levulinic acid and
benzylamine using HBTU and DIEA in DMF.
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The levulinic acid derivative was reacted with myoglobin aldehyde, where it further went
dehydration then an intramolecular aldol reaction, followed by an additional dehydration step
forming a furan ring at the site of conjugation. HPLC trace of the fragment of myoglobin aldehyde
and its bioconjugate product with levulinic acid was obtained to determine the percentage
conversion by calculating the area under the peak. Also, the deconvoluted ESI-MS spectra of
Myoglobin-levulinic acid conjugate was acquired.
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3.5.8 General procedure of the organocatalyzed aldol reaction of peptide ketone-GIRVF with
Salicylaldehyde

To the peptide ketone-GIRVF (7 mM) in 85 % buffer (sodium phosphate buffer, 25 mM, pH 7.5)
with 15% DMSO in a total volume of 300 μL solvent was added salicylaldehyde (84 mM) and OtBu-Thr (100 mM) as a catalyst. The reaction was kept in the heated shaker at 37 °C for 1h. DMSO
was used for ketone-GIRVF solubility.
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3.5.9 General Reaction Scheme for FITC-ketone Synthesis
This modification, conjugation, and analysis was done by Ogonna Nwajiobi at Auburn University.
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3.5.10 General Reaction Scheme for Myoglobin-FITC Synthesis
This modification, conjugation, and analysis was done by Ogonna Nwajiobi at Auburn University.
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3.5.11 General Reaction Scheme for Biotin-ketone Synthesis
This modification, conjugation, and analysis was done by Ogonna Nwajiobi at Auburn University.
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3.5.12 General Reaction Scheme for Myoglobin-biotin Synthesis
This modification, conjugation, and analysis was done by Ogonna Nwajiobi at Auburn University.

123

3.5.13 Role-Reversal: Aldol Conjugation using Protein-Ketone a-lactalbumin

This protein modification, conjugation, and analysis was done by Ogonna Nwajiobi at Auburn
University. a-lactalbumin, which is a protein with glutamic acid at the N-terminus was converted
to a-lactalbumin-ketone using PLP as described in section 3.5.1. HPLC trace of the fragment of

a-lactalbumin ketone and its bioconjugate product with 2-pyridinecarboxaldehyde was obtained.
This was used to determine the percentage conversion by calculating the area under the peak.
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Chapter 4: Synthesis of Homogeneous Antibody Conjugates
4.1 Chapter Objectives

The long-term goal of the project is to apply this methodology for the synthesis of stable antibodydrug conjugates for targeted therapy. The major concerns of current ADCs are regarding their
stability and the inability to control the number of drugs conjugated to the antibody. Thus far, the
stability has been addressed as this method produces bioconjugates that are stable under various
conditions. Also, this method resulted in the synthesis of homogenous conjugation to myoglobin
and α-lactalbumin. In this chapter, this synthesis of homogeneous conjugates using the G110
nanobody as an example will be illustrated. The G110 nanobody will be conjugated to other
biomolecules, peptide-ketones, as well as double labeled with a dye. Additionally, G110 contains
a disulfide linkage and a dye will be conjugated to the nanobody through a thiol-maleimide linkage,
demonstrating this method’s compatibility with cysteine chemistry. Lastly, cellular studies will be
conducted to assess the antibody’s ability to bind its target after undergoing modification.

4.2 Introduction
As described in chapter 1, ADCs are an important class of highly potent drugs utilized for targeted
cancer therapy.1 Antibodies specifically recognize an antigen that is overexpressed on surface of
target/cancer cells, and thus specifically deliver drugs only to a target cell.1 In principle, ADCs can
be used to achieve potent efficacy while minimizing unwanted side effects. The available ADCs
are produced using nonselective conjugation of native amino acids, such as a lysine or a cysteine,
which results in multiple, uncontrollable conjugation sites and thus have varying drug-to-antibody
ratios (DARs) ranging from 0 to 8.2 DARs play a significant role in pharmacokinetics, efficacy,
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and the therapeutic index; heterogeneous ADCs with higher DARs, and thus higher drug loading,
show reduced efficacy as well as faster drug clearance.3 Because of this, there is a great need of
specific conjugation methods for producing ADCs with controlled drug loading as well as an
improved therapeutic index in order to combat the associated toxicity with heterogeneous ADCs.
The aldol organocatalyzed bioconjugation method allows the production of homogeneous ADCs
with the antibody precisely linked to the drug in a controlled antibody-to-drug ratio, optimizing
the biological, physical and pharmacological properties of ADCs.4 Since homogeneous conjugates
are critical for both the safety and efficacy of ADC therapy, I aimed to conjugate a peptide ketoneGIRVF to a single domain antibody, G110. Single domain antibodies, also referred to as
nanobodies, have been shown to be equally specific as normal antibodies and in some cases more
biologically active.

5a,5b

4.3 Results and Discussion

4.3.1 Nanobody G110 and Aldehyde-G110 Synthesis

The synthesis and purification of the nanobody G110 was done by Johannas Yeh at Cold Spring
Harbor Laboratory, Cold Spring Harbor, New York. The nanobody G110 was cloned into
expression vector pET28a with a TEV protease cleavage site in front of the N-terminus of the
nanobody to make the G110 nanobody with a N-terminal glycine. His-tag G110 was cleaved by
adding His-Tag TEV protease (Y’s Lab LLC) to remove the N-terminal histidine tag and leave
only the nanobody with a glycine as the first residue on the N-terminus. The nanobody and TEV
mixture were then passed through a Ni-NTA column and the cleaved G110 nanobody was purified
by collecting from the flow through fraction of the Ni-NTA column.
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G110 binds with high specificity to the epidermal growth factor (EGF) receptor, which is often
amplified in breast cancer cells. The growth factor receptor works by inducing cell differentiation
and proliferation upon activation through the binding of one of its ligands. The G110 nanobody
has no therapeutic activity by itself but can be used to target the breast cancer cell while carrying
a cytotoxic drug. It is small in size, containing only 125 amino acids and a disulfide linkage
between the two cysteine residues. Due to its potential therapeutic benefits, maintaining its
structure is of priority. G110 contains a genetically engineered N-terminal glycine residue, which
was modified to a N-terminal aldehyde using PLP. This aldol bioconjugation method is not limited
by the functionality naturally present at the N-terminus amino acid since an antibody can be
engineered to have an N-terminal glycine.
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4.3.2 Peptide-Ketone and Aldehyde-G110 Conjugate Synthesis
The bioconjugation of ketone-GIRVF to nanobody G110 containing an N-terminal aldehyde was
catalyzed by O-tBu-Thr and produced consistent homogeneous nanobody-drug conjugates (DAR
= 1:1) with 66% conversion.
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Modification of proteins in the presence of free cysteines is particularly challenging due to the
strong nucleophilicity of the thiol group. To assess the compatibility of the aldol organocatalyzed
bioconjugation method with free cysteines, nanobody G110−peptide-AFC conjugate was
synthesized, which resulted in 83% conversion.
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4.3.3 Synthesis of Homogeneous Nanobody Dye Bioconjugate of Nanobody Aldehyde-G110 with
peptide ketone-ACF and Maleimide Dye

Next, the nanobody G110−peptide-AFC conjugate was multiply labeled by reacting the conjugate
with a maleimide dye. The maleimide dye only reacted with the free cysteine of peptide-ACF,
confirming that the mild conditions required for my bioconjugation method maintained the
structurally critical disulfide bond in G110. This is an improvement to traditional ADCs, which
use a variety of linkers to attach drug molecules to antibodies; my method has the capability of
being linker-free. Also, this method can be used when the chemistry for cysteine modification is
not compatible or for applications that require specific labeling at multiple locations through
orthogonal methods. DMSO was used as a co-solvent for the solubility of the maleimide dye.
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4.3.4 Fluorescence Microscopy
Lastly, fluorescence microscopy showed that this labeled G110 nanobody can still bind to an EGF
receptor-expressing breast cancer cell line, MDA-MB468, which confirms the stability of aldol
bioconjugates in cellular assays. Binding of the duel labeled antibody-ACF-dye conjugate lead to
fluorescence. The control reaction was conducted by treating cells with dye but no nanobody-ACF
conjugate, which would not lead to fluorescence since the dye cannot bind the receptor and is
washed away in solution. Another control reaction was done using just the nanobody-ACF
conjugate but lacking dye, which would also not result in fluorescence. This study was done by
Johannes Yeh, Director of CSHL Cancer Center Antibody Shared Resource, at Cold Spring Harbor
Laboratory.
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4.4 Conclusion
I set out to develop a bioorthogonal technique for protein modification. By creating a chemical
strategy that can successfully attach synthetic molecules site specifically to proteins, I have
satisfied this goal. This organocatalyzed aldol bioconjugation reaction involves the introduction of
an exogenous functionality onto a protein, which is then utilized for site-selective conjugation.
This method is applicable to a range of N-terminal residues because of numerous existing methods
to transform the N-terminus into aldehydes and ketones but also because proteins can be
chemically or genetically engineered with an N-terminal alanine or glycine to produce an aldehyde
or ketone, respectively, which was illustrated in this chapter. Using the aldol reaction also allows
the conjugation to occur chemoselectively between aldehydes and ketones only. The use of an
organocatalyst allows the reaction to proceed rapidly under physiological conditions, which is not
only important for maintaining the biomolecules’ structure and function but also for its
contribution to green chemistry and not interfering with cellular studies, which is the case of
residual copper catalyst when performing CuAAC.
The long-term goal of the project is to apply this methodology for the synthesis of stable antibodydrug conjugates for targeted therapy. One major concern of current ADCs is that they are unstable
and synthesized through reversible linkages. This is addressed by using the aldol reaction, which
results in a carbon-carbon bond that has shown to be stable under various conditions. Another
concern was the synthesis of heterogeneous ADCs since they are produced using nonselective
conjugation of native amino acids, such as lysine and cysteine residues, which results in multiple,
uncontrollable conjugation sites and ADCs with varying DARs. This method resulted in the
synthesis of homogenous antibody conjugates using the G110 single domain antibody as an
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example. G110 was conjugated to a peptide-maleimide dye, and like a whole antibody, it is able
to bind selectively to a specific antigen, which was demonstrated. The reaction conditions proved
to be mild enough for successful double labeling of the antibody without disrupting the structure
of the biomolecule or the binding of the antibody to its target. As a bonus, this method is
compatible with cysteine chemistry. All of these findings lead to the conclusion that this
organocatalyzed aldol bioconjugation reaction should be applicable to the synthesis of functional
antibody-drug-conjugates that can successfully deliver payloads to targeted cells.

4.5 Reagents, Experimental Procedures, and Spectral Data
General. All commercial materials (Aldrich, Fluka, Nova) were used without further purification.
All solvents were reagent or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2, and
DMF were obtained from a dry solvent system (passed through a column of alumina) and used
without further drying. All reactions were performed under air in round bottom flasks. Yields refer
to chromatographically pure compounds; % yields were obtained by comparison of HPLC peak
areas of products and starting material. HPLC was used to monitor the reaction progress.

Materials. Fmoc-amino acids were obtained from Nova Biochem (EMD) Millipore Corporation,
Billerica, Massachusetts) and Rink amide, Wang, Chem Matrix and TentaGel resins were obtained
from ChemPrep Inc. (Wellington, Florida). N,N,N′,N′- Tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky).
4-Dimethylaminopyridine (DMAP) was obtained from Merck KGaA (Darmstadt, Germany). N,NDimethylformamide (DMF) was obtained from Macron Fine Chemicals (Center Valley,
Pennsylvania).

Acetonitrile,

N,N-

diisopropylethylamine

(DIEA),

and

N,N'-
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diisopropylcarbodiimide (DIC) were purchased from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts).
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor,
Pennsylvania). Diethyl ether, dichloromethane (DCM), methanol (MeOH), phenylsilane, 1hydroxy-7-azabenzotriazole

(HOAt),

2,4,6-trimethylpyridine,

triphenylphosphine,

tetrahydrofuran (THF), and acetonitrile were obtained from Sigma-Aldrich (St. Louis, Missouri).
Water was purified using a Millipore Milli-Q water purification system.

LC-MS: Peptide compositions were evaluated by high performance liquid chromatography
(HPLC) on an Agilent 1100 series HPLC equipped with a 4.6x150 mm (5μm) C18 column. All
separations used mobile phases of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic
acid (v/v) in acetonitrile (solvent B). A linear gradient of 0– 80% solvent B in 30 minutes at room
temperature with a flow rate of 1.0 mL min-1 was used. The eluent was monitored by UV
absorbance at 220 nm unless otherwise noted. Mass spectrometry to check reaction mixtures was
performed on an Agilent 1100 Series HPLC with MSD VL mass spectrometer using positive
polarity electrospray ionization (+ESI).

LC-HRMS: This analysis was conducted by Ryan Cohen at Merck facilities. High resolution MS
data were acquired using an Agilent 1290 UHPLC with a 6520 Q-ToF mass spectrometer under
positive polarity electrospray ionization (+ESI) with capillary and fragmentor voltages set to 3.5
kV and 175 V, respectively. The instrument was calibrated prior to data acquisition using Agilent’s
reference standard solution, which provided accurate masses within 5 ppm. A reversed phase,
linear gradient separation was performed at a flow rate of 1.0 mL min-1 on a C18 column (Waters
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Acquity UPHLC peptide BEH C18, 1.7 μm particle size, 50 mm x 2.1 mm I.D.) thermostatted at
45°C and gradient from 95% solvent A (0.1% formic acid in water) to 99% solvent B (0.1% formic
acid in acetonitrile) in 4 minutes, followed by 1 minute re-equilibration.

NMR. This analysis was conducted by Ryan Cohen at Merck facilities. Spectral data were
acquired at 25 °C in DMSO-d6 using an Agilent DD2 spectrometer (either 600 MHz or 500 MHz)
equipped with a 3-mm helium triple resonance (HCN) cryoprobe. 1H NMR chemical shifts were
referenced to residual DMSO-d5 at 2.50 ppm, and proton signals were reported as follows:
chemical shifts (dH) in ppm (multiplicity, coupling constants, J in Hz, and integration). Multiplicity
was reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of doublets (dd),
doublet of triplets (td), triplet (t) and multiplet (m). 13C NMR spectra were proton decoupled, and
chemical shifts (dC in ppm) were referenced to DMSO-d6 at 39.52 ppm. 2D NMR spectra were
acquired to further confirm structures and assign proton and carbon signals. Gradient COSY,
gradient TOCSY (80 ms mixing time), gradient ROESY (250 ms mixing time), gradient
multiplicity-edited HSQC (1JCH optimization set to 145 Hz), and gradient HMBC (nJCH
optimization set to 8 Hz) experiments were performed.

Semi-Preparative HPLC. A Beckman Coulter System Gold instrument was used for compound
purification. The instrument was equipped with a 168-diode array detector and a 125P solvent
module. Separations were performed at ambient temperature with a 10 mm x 150 mm (5 µm
particle size) C-18 reversed phase column using an eluent of 0.1% formic acid (v/v) in water
(solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–80%
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solvent B over 30 min with a flow rate of 3.0 mL min-1 was employed. The eluent was monitored
by absorbance at 220 and 254 nm unless otherwise noted.

Analytical HPLC. Analytical HPLC was performed on an Agilent 1100 series HPLC equipped
with a 4.6 mm x 150 mm (3 µm particle size) C-18 reversed phase column. All separations used a
mobile phase of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic acid (v/v) in
acetonitrile (solvent B). A linear gradient of 0–80% solvent B in 30 mins at room temperature with
a flow rate of 1.0 mL min-1 was used. The eluent was monitored by absorbance at 220 nm unless
otherwise noted.

LC-MS conditions for reaction monitoring. Mass spectrometry to check reaction mixtures was
performed using an Agilent 1100 series MSD VL in positive polarity electrospray ionization
(+ESI). This instrument was paired with an Agilent 1100 series HPLC using the previous analytical
HPLC conditions.

High resolution LC-MS conditions for purified peptides. This analysis was conducted by Ryan
Cohen at Merck facilities. Analyses were performed on an ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QToF Premier, Waters) with electrospray ionization (ESI) in positive mode using Mass lynx
software (V4.1). 5 μL of the sample was injected onto a C4 column (WIDEPORE C4 200 Å, LC
Column 50 x 2.1 mm) Phenomenex AerisTM 3.6 μm with a 200 μL/min flow rate of mobile phase
of solution A (95 % H2O, 5% acetonitrile and 0.1% formic acid) and solution B (95% acetonitrile,
5% H2O, and 0.1% formic acid) beginning (gradient time- 0 min 10% B; 5 min 28% B; 20 min
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38% B; 22 min 100% B). Capillary voltage was set at 3.0 kV, the sample cone voltage was 50 V,
and the extraction cone was 4.0 V. The source and desolvation temperature were maintained at 95
and 300 °C, respectively, with the desolvation gas flow at 400 L/h. The Time of Flight Mass
Spectrometry (TOF/MS) scan was 1 s long from 100 to 3200 m/z with an 0.02 s inter-scan delay
using extended dynamic range acquisition and centroid data format. The lock mass was used to
correct instrument accuracy with a 0.5 μM solution of HP 1221 (Agilent part number G196985003). Ion source parameters such as the source temperature (gas and sample cone), mobile phase
flow rate, and cone voltage were fixed throughout the study.

Fmoc Solid-Phase Peptide Synthesis6 Peptides were synthesized manually on a 0.25 mm scale
using Rink amide resins. The Fmoc group was deprotected using 20% piperidine–DMF for 20 min
to obtain a deprotected peptide resin. Fmoc-protected amino acids (1.25 mm) were sequentially
coupled on the resin using HBTU (1.25 mm) and DIEA (1.25 mm) for 2 h at room temperature.
Peptides were synthesized using standard protocols.1 The peptide was cleaved from the resin using
a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 h. The resin was
removed by filtration and the resulting solution was concentrated. The oily residue was triturated
with diethyl ether to obtain a white suspension. The resulting solid was purified by semipreparative HPLC.
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4.5.1 General Procedure for the Synthesis of Nanobody, Nanobody Aldehyde, and Peptide
Ketones7

The synthesis and purification of the nanobody G110 was done by Johannas Yeh at Cold Spring
Harbor Laboratory, Cold Spring Harbor, New York. The nanobody G110 was cloned into
expression vector pET28a with a TEV protease cleavage site in front of the N-terminus of the
nanobody. BL21(DE3) pLys cells were used to express the protein. To induce the protein
production, cells were grown at 37oC until OD600 reached to 1 and then induced with IPTG (0.1mM
final concentration) at 30oC for 4 hours. Cells were harvested by centrifugation and the cell pellets
were lysed by sonication with pH 7.5 in 20mM sodium phosphate buffer, followed by Ni-NTA
(GE Healthcare Inc.) purification of the His-Tag G110. To make the G110 nanobody with a Nterminal glycine. His-tag G110 was cleaved by adding His-Tag TEV protease (Y’s Lab LLC) to
remove the N-terminal histidine tag and leave only the nanobody with a glycine as the first residue
on the N-terminus. The nanobody and TEV mixture were then passed through a Ni-NTA column
again and the cleaved G110 nanobody was purified by collecting from the flow through fraction
of the Ni-NTA column.
The Nanobody G110 Sequence is as follows :
GGSQVQLQESGGGSVQAGGSLKLSCAASGRGFSRYAMGWFRQAPGQDREFVATISWT
NSTDYADSVKGRFAISRDNAKNTAYLQMNSLKPEDTAVYYCAADKWASSTRSIDYDY
WGQGIQVTVSS
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A nanobody G110 with glycine at the N-terminus (5mg) was dissolved in 25 mM sodium
phosphate buffer (pH 6.5). The protein aldehyde was prepared as described in section 3.5.1. The
pH was monitored with a microelectrode and adjusted to 6.5 to prevent the solution from being
overly acidic, which could lead to protein precipitation or suboptimal levels of conversion.

The PLP stock solution was added to the protein solution in a 1:1 volume ratio. Combine nanobody
G110 solution and the PLP stock solution to give a final concentration of 10 mM PLP and 10 500 μM nanobody G110 at pH 6.5. Incubate at 37 °C for 4–20 h.
The pure protein and protein aldehyde were analyzed by ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QTof Premier, Waters).

Peptides with alanine (5mg) at the N-terminus was converted to a peptide-ketone using PLP as
described in section 3.5.1.
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4.5.2 General procedure for synthesis of homogeneous nanobody bioconjugate of nanobody
aldehyde-G110 with peptide ketone-GIRVF
To a nanobody G110 aldehyde (0.15 mM) in 85 % buffer (sodium phosphate buffer, 25 mM, pH
7.5) with 15% DMSO in a total volume of 300 μL solvent was added ketone- GIRVF 17 (10 mM)
and O-tBu-Thr (100 mM) as a catalyst. The reaction was kept on a shaker at 37 °C for 1h. DMSO
was used for ketone-GIRVF solubility. The reaction was analyzed by ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QTof Premier, Waters).

4.5.3 General procedure for synthesis of homogeneous nanobody bioconjugate of nanobody
aldehyde-G110 with peptide ketone-ACF
To a nanobody G110 aldehyde (0.15 mM) in 100 % buffer (sodium phosphate buffer, 25 mM, pH
7.5) was added ketone-ACF (10 mM) and O-tBu-Thr (100 mM) as a catalyst. The reaction was
kept on a shaker at 37 °C for 1h. The reaction was analyzed by ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QTof Premier, Waters).

4.5.4 General procedure for synthesis of homogeneous nanobody dye bioconjugate of nanobody
aldehyde-G110 with peptide ketone-ACF and maleimide dye
To a nanobody G110 aldehyde (0.15 mM) in 100 % buffer (sodium phosphate buffer, 25 mM, pH
7.5) was added ketone-ACF (10 mM) and O-tBu-Thr (100 mM) as a catalyst. The reaction was
kept on a shaker at 37 °C for 1h. After the removal of excess ketone-ACF and catalyst O-tBu-Thr
from the reaction mixture using molecular cut off centrifuge. The resulting aldol bioconjugate in
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buffer (sodium phosphate buffer, 25 mM, pH 7.5) and 20 % DMSO was reacted with maleimide
dye (5 equiv.) and the reaction was left on shaker for 12 h. DMSO was used for maleimide dye
solubility. The reaction was analyzed by ultra-performance LC system (ACQUITY, Waters Corp.,
USA) coupled with a quadrupole time-of-flight mass spectrometer (Q-Tof Premier, Waters).
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Chapter

5:

Site-Selective

N-terminal

Asparagine

and

Glutamine

Bioconjugation

5.1 Chapter Objectives
In chapters 2 through 4, I developed a site-selective protein modification technique based on
conjugation at a non-native functional handle, an aldehyde or ketone, that was chemically
introduced onto the biomolecules before undergoing the organocatalyzed aldol reaction. In this
chapter, the focus will be on the development of a bioconjugation technique based on a native
functionality found on proteins. The site of interest is the a-amine of the N-terminus, which stands
out as a unique reactive site for site-specific modification strategies. Both asparagine (Asn, N) and
glutamine (Gln, Q) are capable of reacting with an aldehyde and forming a bioconjugate product,
just like other amino acids such as cysteine, serine, threonine, and tryptophan. N-terminal Asn/Gln
chemistry will be utilized to synthesize bioconjugates for the first time. Also, all 20 common amino
acids will be screened to in order to determine their reactivity with aldehydes at neutral pH. The
ultimate goal is to apply this methodology to proteins for various applications, including protein
purification and synthesis of homogeneous antibody-drug-conjugates.

5.2 Introduction
As described in chapter 1, many methods have been developed to conjugate a molecule to native
functionalities present in proteins via amino acid side-chains, such as lysine, cysteine, tyrosine,
and tryptophan. When applied to protein labeling, these reactions tend to be non-selective since
proteins contain multiple copies of targeted residues on their surface that are usually present in
large quantities and hinder selectivity. Bioconjugation methods dependent on the presence of
146

native amino acid residues often lack chemoselectivity and efficiency. However, targeting an
amino acid that is adjacent to the a-amine of the N-terminus is a promising, unique site of interest
for site-selective conjugation. Even with their large size, the termini of proteins are usually highly
accessible for chemical modification; in fact, 80.3% of N-terminal residues are solvent exposed
and can be extended without disruption of the protein’s structure.1

Valuable modification methods have been developed that take advantage of natural amino acids
at the N-terminus. I have utilized some of these reactions in my own research. The organocatalyzed
aldol bioconjugation reaction uses N-terminal serine and threonine residues and converts them into
aldehydes, as described in chapter 2. Also, multiple amino acids at the N-terminus are converted
into aldehydes and ketones using PLP or RS, as described in chapter 3. NCL as well as aldehyde
condensation reactions with N-terminal cysteines, serine, threonine, and tryptophan are also wellknown reactions that will be described in detail. The development of this asparagine and glutamine
selective bioconjugation method will add to the toolbox of chemical reactions that can be
employed.

5.2.1 Site-Selective N-terminal Modification Strategies
Proteins with cysteines at the N-termini are modified through two well-known strategies. The first
method, native chemical ligation (NCL) is a reaction between the thiol group of an N-terminal
cystine and a C-terminal thioester, assisted by thiol catalysts.2a,2b This ligation method is
traditionally used in chemical peptide synthesis to ligate two unprotected peptides, resulting in
formation of an amide bond between the two peptides. The first step in the mechanism is a
reversible transthioesterification reaction followed by S,N-acyl shift, resulting in a polypeptide

147

chain that contains a cysteine at the site of ligation. The other reaction of N-terminal cysteine is
condensation with aldehydes to form the thiazolidines. 3a,3b The cyclization of cysteines with
aldehydes to form thiazolidines is relatively slow and requires acidic conditions (pH 4–5). Also,
the resulting product stability is not promising; the thiazolidine product is prone to hydrolysis,
depending on the pH and temperature.4

Serine and threonine residues located at the N-terminus of peptides and proteins can undergo
oxidative cleavage through oxidation with sodium periodate (NaIO4), resulting in formation of an
aldehyde that can further undergo reactions with alkoxyamines to make oximes or ketones to make
b-hydroxy ketones.5 This methodology has also been used is for capturing serine and threonine
containing peptides out of a mixture for purification and identification purposes.6 Unmodified Nterminal serine or threonine residues can also undergo condensation with aldehydes to form
oxazolidines.7 Serine derived oxazolidines are found to disrupt protein’s secondary structure and
is also prone to hydrolysis.8a,8b

Lastly, tryptophan residues at the N-terminus of proteins can undergo Pictet–Spengler reaction,
which is when a b-arylethylamine and aldehyde or ketone moiety undergoes aldehyde
condensation. Following formation of an iminium ion, the product then undergoes ring closure and
cyclizes with the aldehyde.9a,9b Just like the classic Pictet–Spengler carbon-carbon bond forming
reaction between tryptamine and an aldehyde, the reaction on proteins occurs under acidic pH and
elevated temperatures, which can potentially disrupt the structure of proteins.10 Despite their
limitations, all of these methods are employed as methods for site-selectivity at the N-terminal of
proteins.
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5.2.2 Asparagine Chemistry
In literature, the unique functionality at N-terminal asparagine was used to design a dynamic
polymerization network resulting in biopolymers that are sequence specific. The biopolymers
created include both linear and cyclic dimers and trimers as well as more complex oligomers
including beta sheets. This is achieved by using small peptide fragments that contain N-terminal
asparagine and a C-terminal aldehyde. The reaction proceeds acidic aqueous acetonitrile solution
at 24 °C.11

5.2.3 Proposed Mechanism of Asparagine Selective Bioconjugation
Asparagine at the N-terminus of peptides and proteins contain an α-amino group and a side chain
carboxamide. Upon reaction with an aldehyde containing peptide, the α-amino group undergoes
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nucleophilic addition to the aldehyde, resulting in an imine intermediate. Next, the side chain
carboxamide adds to the imine, resulting in an aminal at the site of ligation and formation of a
ketopiperazine derivative. This proposed mechanism leads to the formation of a stable
bioconjugate that is selective from N-terminal asparagine. This methodology can also be applied
to that of glutamine, which results in formation of a 7-member ring at the site of conjugation.

5.3 Results and Data
5.3.1 Chemoselectivity
An initial model study was done to determine if N-terminal asparagine was capable of undergoing
reaction with a peptide aldehyde at neutral pH as well as its chemoselectivity over other N-terminal
amino acids. For this study, peptides were synthesized with the NH2-XAF sequence, where X is
one of 20 amino acids at the N-terminus. These peptides were reacted with peptide aldehyde-VF,
which was synthesized from reaction of NH2-SVF and NaIO4 as described in chapter 2. This
screening showed that asparagine (N) and glutamine (Q) were the most successful at forming the
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bioconjugate under the reaction conditions, with 90% and 83% conversions, respectively. The only
other amino acids that reacted under these conditions were cysteine (C), serine (S), threonine (T),
and tryptophan (W). These products were expected and are well-known in literature, as described
in the introduction, however they resulted in moderate to poor conversion under these reaction
conditions.

In order to expand the substrate scope, peptides containing N-terminal asparagine were synthesized
and reacted with peptide aldehyde-VF. In addition to NH2-NAF, peptides NH2-NNAE (oall) and
NH2-NFLAFS also showed successful conversion to the conjugate with 92% and 93%
conversions, respectively. The glutamic acid (E) side chain contains the OAll protecting group
only because the peptide was already synthesized and available; the protecting group does not
affect the conversion to product. Also, peptide NH2-NNAE(oall) contains an internal asparagine
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in addition to the one located at the N-terminus. Successful conjugation at the N-terminal
asparagine confirms the reaction’s selectivity at the N-terminus. The conjugate product mass is the
addition of the two reactants, followed by removal of water. The imine intermediate and aminal
final product are of the same mass and were later differentiated following stability studies and
HSQC NMR analysis. The reaction was purified by injecting the sample into the HPLC after 24h
and analyzed by LCMS. The conjugated product of N-terminal asparagine containing peptide NH2NNAE(oall) was analyzed by NMR.
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5.3.2 Solvent Screening
A solvent screening using NH2-NFLAFS and peptide aldehyde-VF shows the reaction does not
work in a completely aqueous environment and requires organic solvent. The reaction also
performs better in an equal mixture of DMF as compared to DMSO. Both solvents are dipolar
aprotic solvents with similar physical properties; DMSO is slightly more polar and is considered
a safer alternative to DMF. DMF is a carcinogen that can cause liver disease and affect
reproductivity, which raises toxicity concerns for the handler.12a,12b Future studies will include
optimization of the solvent system for a safer reaction.
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5.3.3 Conjugate Stability Studies
The reversible imine would not be stable for under the testing conditions, which was the first
indication that the structure was that of the aminal and not the imine. The study was done by
incubating the aldehyde-VF and NH2-NNAE (oall) conjugate product in 10 mM sodium phosphate
buffer at varying pHs ranging from 4.3 to 10.3 for 24 hours at a slightly elevated temperature
(37°C). No product degradation was observed of the conjugated product over this time period. The
progress of the reaction was monitored by injecting the sample into the HPLC after regular
intervals of time.
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5.3.4 Aminal vs. Imine Structures
An NMR analysis by Ryan Cohen was conducted in order to assess whether the conjugated product
formed was the aminal or the imine structure. 13C chemical shifts were predicted using the QSPR
model and estimated a 64 ppm chemical shift for the aminal carbon and a 156.5 ppm chemical
shift for the imine carbon. The actual NMR data obtained for the aldehyde-VF and peptide NH2NNAE (oall) conjugated product is consistent with the aminal structure. The two-dimensional
spectrum used in this analysis, HSQC, has one axis for proton and the other for 13C; the spectrum
contains a peak for each unique proton attached to the heteronucleus being considered. Two aminal
protons with 13C chemical shifts of 65.2 ppm and 66.5 ppm are present. In the region of 150-165
ppm, where the imine chemical shift is expected, there are no signals present. This confirms the
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carbon is that of the aminal structure and not the imine, which is consistent with the stability
studies.
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5.3.5 Glutamine Selective Bioconjugation
After conjugating peptide aldehydes with N-terminal asparagine containing peptides, glutamine
was also assessed for site-selective conjugation with aldehydes since it showed success during the
initial peptide screening study. Glutamine’s side chain is structurally similar to that of asparagine
except it contains an extra carbon. The resulting conjugate formed with contain a 7-member ring
at the site of conjugation. Peptide aldehyde-VF and N-terminal glutamine containing peptide NH2QAF were reacted in 50% DMF in 10 mM sodium phosphate buffer for 24hr at 37°C. The reaction
was purified by HPLC and analyzed by HRMS (HRMS done by Ryan Cohen at Merck).
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5.4 Conclusions
In this chapter, peptides aldehyde-VF and aldehyde-IGSLAK were conjugated to asparagine
containing peptides, showing success in a DMF and buffer mixture at neutral pH. This work can
be further developed by optimizing reaction conditions using different solvents and performing
time studies to determine when the reaction is complete. Another avenue is expanding the substrate
scope to include more aldehydes, such as aryl and protein aldehydes. In the screening studies, the
asparagine and glutamine peptides showed greater success than the reactions of peptides
containing N-terminal cysteine, serine, threonine, and tryptophan, which work better under acidic
conditions. Their applicability to proteins is limited due to the requirement of an acidic
environment. This asparagine/glutamine selective bioconjugation technique has the ability to
effectively produce conjugates in a biological environment, which can be used for the labeling of
proteins with asparagine or glutamine naturally present or engineered at the N-terminus or utilized
for the synthesis of homogeneous antibody-drug conjugates like the aldol bioconjugation
methodology developed in chapters 2-5.

5.5 Experimental Procedures and Spectral Data
General: All commercial materials (Sigma-Aldrich, Fluka, and Novabiochem) were used without
further purification. All solvents were reagent or HPLC (Fisher) grade. Diethyl ether,
dichloromethane, and N,N-dimethylformamide were obtained from a dry solvent system (passed
through an alumina column) and used without further drying. All reactions were performed under
air in glass vials. HPLC was used to monitor reaction progress.
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Materials: Fmoc-amino acids were obtained from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained
from ChemPep Inc. (Wellington, Florida). N,N,N′,N′- Tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky).
4-Dimethylaminopyridine (DMAP) was obtained from Merck KGaA (Darmstadt, Germany). N,NDimethylformamide (DMF) was obtained from Macron Fine Chemicals (Center Valley,
Pennsylvania).

Acetonitrile,

N,N-

diisopropylethylamine

(DIEA),

and

N,N'-

diisopropylcarbodiimide (DIC) were purchased from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts).
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor,
Pennsylvania). Diethyl ether, dichloromethane (DCM), methanol (MeOH), phenylsilane, 1hydroxy-7-azabenzotriazole

(HOAt),

2,4,6-trimethylpyridine,

triphenylphosphine,

tetrahydrofuran (THF), and acetonitrile were obtained from Sigma-Aldrich (St. Louis, Missouri).
Water was purified using a Millipore Milli-Q water purification system.
LC-MS: Peptide compositions were evaluated by high performance liquid chromatography
(HPLC) on an Agilent 1100 series HPLC equipped with a 4.6x150 mm (5μm) C18 column. All
separations used mobile phases of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic
acid (v/v) in acetonitrile (solvent B). A linear gradient of 0– 80% solvent B in 30 minutes at room
temperature with a flow rate of 1.0 mL min-1 was used. The eluent was monitored by UV
absorbance at 220 nm unless otherwise noted. Mass spectrometry to check reaction mixtures was
performed on an Agilent 1100 Series HPLC with MSD VL mass spectrometer using positive
polarity electrospray ionization (+ESI).
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NMR. This analysis was conducted by Ryan Cohen at Merck facilities. Spectral data were
acquired at 25 °C in DMSO-d6 using an Agilent DD2 spectrometer (either 600 MHz or 500 MHz)
equipped with a 3-mm helium triple resonance (HCN) cryoprobe. 1H NMR chemical shifts were
referenced to residual DMSO-d5 at 2.50 ppm, and proton signals were reported as follows:
chemical shifts (äH) in ppm (multiplicity, coupling constants, J in Hz, and integration).
Multiplicity was reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of doublets
(dd), doublet of triplets (td), triplet (t) and multiplet (m). 13C NMR spectra were proton decoupled,
and chemical shifts (äC in ppm) were referenced to DMSO-d6 at 39.52 ppm. 2D NMR spectra
were acquired to further confirm structures and assign proton and carbon signals. Gradient COSY,
gradient TOCSY (80 ms mixing time), gradient ROESY (250 ms mixing time), gradient
multiplicity-edited HSQC (1JCH optimization set to 145 Hz), and gradient HMBC (nJCH
optimization set to 8 Hz) experiments were performed.
Semi-Preparative HPLC. A Beckman Coulter System Gold instrument was used for compound
purification. The instrument was equipped with a 168-diode array detector and a 125P solvent
module. Separations were performed at ambient temperature with a 10 mm x 150 mm (5 ìm
particle size) C-18 reversed phase column using an eluent of 0.1% formic acid (v/v) in water
(solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–80%
solvent B over 30 min with a flow rate of 3.0 mL min-1 was employed. The eluent was monitored
by absorbance at 220 and 254 nm unless otherwise noted.
Analytical HPLC. Analytical HPLC was performed on an Agilent 1100 series HPLC equipped
with a 4.6 mm x 150 mm (3 µm particle size) C-18 reversed phase column. All separations used a
mobile phase of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic acid (v/v) in
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acetonitrile (solvent B). A linear gradient of 0–80% solvent B in 30 mins at room temperature with
a flow rate of 1.0 mL min-1 was used. The eluent was monitored by absorbance at 220 nm unless
otherwise noted.
LC-MS conditions for reaction monitoring. Mass spectrometry to check reaction mixtures was
performed using an Agilent 1100 series MSD VL in positive polarity electrospray ionization
(+ESI). This instrument was paired with an Agilent 1100 series HPLC using the previous analytical
HPLC conditions.
LC-HRMS for NH2-QAF and peptide aldehyde-VF conjugate: This analysis was conducted
by Ryan Cohen at Merck facilities. High resolution MS data were acquired using an Agilent 1290
UHPLC with a 6520 Q-ToF mass spectrometer under positive polarity electrospray ionization
(+ESI) with capillary and fragmentor voltages set to 3.5 kV and 175 V, respectively. The
instrument was calibrated prior to data acquisition using Agilent’s reference standard solution,
which provided accurate masses within 5 ppm. A reversed phase, linear gradient separation was
performed at a flow rate of 1.0 mL min-1 on a C18 column (Waters Acquity UPHLC peptide BEH
C18, 1.7 μm particle size, 50 mm x 2.1 mm I.D.) thermostatted at 45°C and gradient from 95%
solvent A (0.1% formic acid in water) to 99% solvent B (0.1% formic acid in acetonitrile) in 4
minutes, followed by 1 minute re-equilibration.
High resolution LC-MS conditions for purified peptides. This analysis was conducted by Ryan
Cohen at Merck facilities. Analyses were performed on an ultra-performance LC system
(ACQUITY, Waters Corp., USA) coupled with a quadrupole time-of-flight mass spectrometer (QToF Premier, Waters) with electrospray ionization (ESI) in positive mode using Mass lynx
software (V4.1). 5 μL of the sample was injected onto a C4 column (WIDEPORE C4 200 Å, LC
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Column 50 x 2.1 mm) Phenomenex AerisTM 3.6 μm with a 200 μL/min flow rate of mobile phase
of solution A (95 % H2O, 5% acetonitrile and 0.1% formic acid) and solution B (95% acetonitrile,
5% H2O, and 0.1% formic acid) beginning (gradient time- 0 min 10% B; 5 min 28% B; 20 min
38% B; 22 min 100% B). Capillary voltage was set at 3.0 kV, the sample cone voltage was 50 V,
and the extraction cone was 4.0 V. The source and desolvation temperature were maintained at 95
and 300 °C, respectively, with the desolvation gas flow at 400 L/h. The Time of Flight Mass
Spectrometry (TOF/MS) scan was 1 s long from 100 to 3200 m/z with an 0.02 s inter-scan delay
using extended dynamic range acquisition and centroid data format. The lock mass was used to
correct instrument accuracy with a 0.5 μM solution of HP 1221 (Agilent part number G196985003). Ion source parameters such as the source temperature (gas and sample cone), mobile phase
flow rate, and cone voltage were fixed throughout the study.
Fmoc Solid-Phase Peptide Synthesis12 Peptides were synthesized manually on a 0.25 mm scale
using Rink amide resins. The Fmoc group was deprotected using 20% piperidine–DMF for 20 min
to obtain a deprotected peptide resin. Fmoc-protected amino acids (1.25 mm) were sequentially
coupled on the resin using HBTU (1.25 mm) and DIEA (1.25 mm) for 2 h at room temperature.
Peptides were synthesized using standard protocols.1 The peptide was cleaved from the resin using
a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 h. The resin was
removed by filtration and the resulting solution was concentrated. The oily residue was triturated
with diethyl ether to obtain a white suspension. The resulting solid was purified by semipreparative HPLC.
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5.5.1 General procedure for the synthesis of peptide aldehydes
To peptides with serine at the N-terminus (1 eq.) in 50 mM sodium phosphate buffer (pH 7.5) was
added sodium periodate (5 eq.), and the reaction was stirred at room temperature for 3 h. Unreacted
sodium periodate was removed by filtration, and the resulting peptide aldehyde was purified by
HPLC. The pure peptide aldehydes were analyzed by MS and NMR.
5.5.2 General procedure for the reaction of peptide aldehyde with NH2-XAF

Reaction conditions: NH2-XAF peptide (2.6 mM), aldehyde-VF (7 mM), 37°C, 24h in 50% DMF
in 10mM Sodium Phosphate Buffer (pH 7.5). Reaction total volume used was 400 µl.

5.5.3 Additional Data
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Peptide NH2-AKFGF reaction with aldehyde-VF did not result in successful conjugation.

Peptide NH2-CRAFS reaction with peptide aldehyde-VF did result in successful conjugation as
expected with 22% conversion.
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Chapter 6: Conclusions and Contributions to Knowledge

6.1 Conclusions and Contributions
6.1.1 Organocatalyzed Aldol Bioconjugation

The organocatalyzed aldol bioconjugation technique is rapid, compatible with physiological
conditions, and irreversible with a covalent linkage that is strong and inert to biological conditions.
This reaction is chemoselective, resulting only in a reaction between the aldehyde and the ketone
in the presence of various reactive function groups naturally present on peptides and proteins. The
n-terminal aldehyde or ketone modification and subsequent aldol reaction takes place site
specifically, allowing for controllable conjugation at one particular location on the biomolecule.
Amino acids are used as organocatalysts, allowing the reaction to proceed rapidly under
physiological and cellular conditions, which is not only important for maintaining the
biomolecules’ structure and function but also for its contribution to green chemistry.

The long-term goal of the project is to apply this methodology for the synthesis of stable antibodydrug conjugates for targeted therapy. Antibody-conjugates were successfully synthesized, and in
the future, this method can be used to deliver drugs to targeted cells. Concerns about the stability
of current ADCs can be combated by using the aldol reaction, which results in a carbon-carbon
bond that has shown to be stable under various reaction conditions. Another concern was the
synthesis of heterogeneous ADCs since current methods results in multiple, uncontrollable
conjugation sites and ADCs with varying DARs. The organocatalyzed aldol bioconjugation
method resulted in the synthesis of homogenous antibodies using the G110 single domain antibody
as an example. The reaction conditions proved to be mild enough for successful double labeling
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of the antibody without disrupting the structure of proteins or the binding of the antibody to its
target. All of these findings lead to the conclusion that this organocatalyzed aldol bioconjugation
reaction should be applicable to the synthesis of functional antibody-drug-conjugates that can
successfully deliver payloads to targeted cells. This work is published in Organic Letters.

6.1.2 Asparagine and Glutamine Selective Bioconjugation
There are many reactions that take advantage of the uniquely reactive a-amine on the N-terminus
of peptides and proteins. The asparagine and glutamine selective bioconjugation reaction is another
technique to do so. Peptide-aldehydes were conjugated to asparagine containing peptides, showing
success in a DMF and buffer mixture at neutral pH. In the screening studies, the asparagine and
glutamine peptides showed greater success than the reactions of peptides containing n-terminal
cysteine, serine, threonine, and tryptophan, which work better under acidic conditions; their
applicability to proteins is limited due to the requirement of an acidic environment. This asparagine
and glutamine selective bioconjugation technique has the ability to effectively produce conjugates
in a biological environment, which can be used for the labeling of proteins with asparagine or
glutamine naturally present or engineered at the N-terminus or even utilized for the synthesis of
homogeneous antibody-drug conjugates like the organocatalyzed aldol bioconjugation method.
This work is currently unpublished and is to be completed under Dr. Monika Raj at Auburn
University.
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